

1 **IL-32 producing CD8⁺ memory T cells and Tregs define the IDO1 / PD-L1 niche in**
2 **human cutaneous leishmaniasis skin lesions.**

3

4 Nidhi S. Dey¹, Shoumit Dey¹, Naj Brown¹, Sujai Senarathne², Luiza Campos Reis^{3,¥}, Ritika
5 Sengupta⁴, Jose Angelo L. Lindoso^{5,6}, Sally James⁷, Lesley Gilbert⁷, Mitali Chatterjee⁴, Hiro
6 Goto³, Shalindra Ranasinghe² and Paul M. Kaye^{1*}

7

8 ¹York Biomedical Research Institute, Hull York Medical School, University of York, UK.

9 ²Department of Parasitology, Faculty of Medical Sciences, University of Sri
10 Jayewardenepura, Sri Lanka.

11 ³Department of Preventive Medicine, Instituto de Medicina Tropical de São Paulo, Faculdade
12 de Medicina, Universidade de São Paulo, Brazil.

13 ⁴Department of Pharmacology, Institute of Postgraduate Medical Education and Research,
14 Kolkata, India.

15 ⁵Secretaria de Saúde do Estado de São Paulo, Instituto de Infectologia Emílio Ribas, São
16 Paulo, SP, Brasil

17 ⁶University of São Paulo, Faculty of Medicine, Department of Infectious and Parasitic
18 Diseases, São Paulo, SP, Brazil.

19 ⁷Technology Facility, Department of Biology, University of York, York, YO10 5DD

20

21 *Correspondence: Paul M. Kaye, paul.kaye@york.ac.uk

22

23 [¥] Current address: Escuela Profesional de Medicina Humana, Facultad de Medicina,
24 Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas, Chachapoyas, Peru.

25

26 **Key words:** Human cutaneous leishmaniasis, Host directed therapy, skin, IL-32, CD8

27 memory T cells, Regulatory T cells, Prognosis, Spatial Transcriptomics, IDO1, PD-L1,

28 myeloid cells.

29 Total words = 4371 (excluding methods, abstract, figure legends and references)

30


31 **Abstract**

32 Human cutaneous leishmaniasis (CL) is characterised by chronic skin pathology.
33 Experimental and clinical data suggest that immune checkpoints (ICs) play a crucial role in
34 disease outcome but the cellular and molecular niches that facilitate IC expression during
35 leishmaniasis are ill-defined. We previously showed that in Sri Lankan patients with CL,
36 indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) are enriched
37 in lesion skin and that reduced PD-L1 expression early after treatment onset predicted cure
38 rate following antimonial therapy. Here, we use spatial cell interaction mapping to identify
39 IL-32-expressing CD8⁺ memory cells and regulatory T cells as key components of the IDO1 /
40 PD-L1 niche in Sri Lankan CL patients and in patients with distinct forms of dermal
41 leishmaniasis in Brazil and India. Furthermore, the abundance of IL-32⁺ cells and IL-
42 32⁺CD8⁺ T cells at treatment onset was prognostic for rate of cure in Sri Lankan patients.
43 This study provides a unique spatial perspective on the mechanisms underpinning IC
44 expression during CL and a novel route to identify additional biomarkers of treatment
45 response.

46

47 Graphical Abstract

48



49

50 Introduction

51 Cutaneous leishmaniasis (CL) is caused by protozoan parasites of the genus *Leishmania* and
52 exhibits a wide spectrum of clinical presentations determined at least in part by the host
53 immune response. *Leishmania* are intracellular parasites of myeloid cells, predominantly
54 macrophages, monocytes, and dendritic cells^{1,2,3}. Consequently, protective immunity is
55 largely cell-mediated, with effector CD4⁺ and CD8⁺ T cells producing cytokines (e.g. IFN γ)
56 that activate myeloid cell-intrinsic leishmanicidal activity^{4,5}. Over-exuberant or persistent
57 effector T cell function at the site of infection can lead to tissue damage and progression of
58 clinical disease despite a reduction in parasite load⁶. Conversely, parasite persistence has
59 been attributed to a combination of dysregulation of the T cell response and parasite-
60 mediated subversion of epigenetic and transcriptional pathways that control macrophage
61 polarisation and activation⁷.

62
63 Studies in animal models have elegantly demonstrated the impact of dichotomy in CD4⁺ T
64 cell responses to *Leishmania*. For example, enhanced CD4⁺ Th2 responses⁸ are responsible
65 for the genetically determined susceptibility of BALB/c mice to *L. major* infection and IL-4-
66 driven alternatively activated macrophages favour parasite survival⁹. This dichotomy in
67 CD4⁺ T cell response has some parallels in human leishmaniasis. Strong Th1 responses are
68 associated with resolution of infection in CL patients infected with *L. donovani* in Sri Lanka⁹
69 and with *L. major* in Iran¹⁰, whereas increased lesional IL-4 was observed in Sri Lankan
70 patients with a poor response to treatment¹¹. However, chronic stimulation of CD4⁺ Th1
71 cells leads to differentiation into Tr1 cells producing IL-10, a well-known inhibitor of IFN γ -
72 mediated NO production¹². Regulatory T cells producing IL-10 have also been associated
73 with parasite latency, treatment resistance, and disease relapse in humans^{13,14}. In *L.*
74 *braziliensis* infection, chronic lesion development occurs in the face of relatively low parasite

75 burden and has been most commonly associated with an over-exuberant cytolytic CD8⁺ T
76 cell response¹⁵.

77

78 In leishmaniasis¹⁶ as well as many other infectious¹⁷ and non-infectious^{18,19} diseases, the
79 role of immune checkpoints (ICs) as regulators of T cell effector function and disease
80 outcome has been well described. For example, indoleamine-2,3-dioxygenase (IDO1) is a
81 metabolic IC molecule expressed in response to inflammatory insults by macrophages²⁰,
82 dendritic cells²¹ and B cells²² and catalyses degradation of tryptophan²³. Tryptophan
83 starvation in T cells leads to proliferation arrest²³, anergy²⁴ or regulatory phenotypes²⁵,
84 facilitating tumour immune escape²⁶ or in the case of CL lesion progression²⁷. Similarly,
85 programmed death ligand 1 (PD-L1; *CD274*) is expressed by myeloid cells upon activation
86 via LPS/IFN- γ or IL-4 and when bound to PD-1 on T cells inhibits activation and promotes
87 IL-10 expression²⁸. These and other ICs have become invaluable prognostic and therapeutic
88 targets in cancer. Co-expression of PD-L1 and IDO1 in resected non-small cell lung cancer
89 (NSCLC) may predict survival outcome²⁹ and triple blockade of IDO1, PD-L1 and
90 MAPK/ERK kinase has been proposed as therapy in NSCLC³⁰. In a similar vein, an
91 immunomodulatory vaccine targeting IDO1⁺PD-L1⁺ myeloid cells is under development for
92 metastatic melanoma³¹. In addition to modulating the natural course of disease, ICs may
93 also play a role in tempering the efficacy of conventional but immune-dependent anti-
94 infectives and anti-cancer drugs. For example, we recently demonstrated that PD-L1 and
95 IDO1 are enriched in skin lesions of CL patients in Sri Lanka and that a decrease in PD-L1
96 expression early after treatment onset was predictive of rate of cure following treatment with
97 sodium stibogluconate, a well-known immune dependent drug³².

98 Despite many examples of disease-associated aberrant expression of IDO1 and PD-L1^{33, 34, 35,}
99 ^{36, 37, 38}, our understanding of the cellular and molecular pathways that regulate expression of

100 the ICs is largely derived from in vitro studies. Multiple cytokines and inflammatory signals
101 can induce IDO1^{39,40} and PD-L1^{41,42} expression on human monocytes and DCs, including
102 IFN γ , TNF, TGF- β , IL-6, IL-10, IL-27, IL-32, PAMPs/DAMPs, and PGE2. IDO1 and PD-
103 L1 are also induced by intracellular infection with *Leishmania*^{32,43,44} and other pathogens^{45,}
104 ⁴⁶ suggesting that subversion of host cell function by manipulation of ICs is a conserved
105 mechanism across pathogen evolution. There is currently little understanding, however, of
106 how these ICs are regulated in the complex spatial microenvironments associated with
107 chronic tissue pathology that result from either infection or cancer.

108

109 Here, we have combined multiple spatial methodologies to define the cellular and
110 transcriptomic composition of niches containing IDO1⁺ and PD-L1⁺ myeloid cells in tissue
111 biopsies from Sri Lankan CL patients and patients with other diverse forms of dermal
112 leishmaniasis. Our results reveal diversity in niche composition and localisation, but identify
113 IL-32⁺ CD8⁺ T cells and IL-32⁺ Tregs as common attributes of these immunoregulatory
114 microenvironments.

115

116 **Results**

117 ***CD274* and *IDO1* localise to myeloid cell-rich niches**

118 To understand the cellular and molecular architecture of human CL lesions, we conducted
119 Visium spatial transcriptomics on FFPE sections from 6 patients (P1-P6; **Supplementary**
120 **Table 1**) presenting with a papular and/or ulcerative plaque lesion typical of Sri Lankan CL
121 (SL_CL) (**Fig.1a** and **Extended Data Fig.1a**). H&E staining and immunochemistry revealed
122 dense cellular infiltration and parasitism in the papillary dermis (**Fig.1b** and **Extended Data**
123 **Fig.1b**). A total of 2418 Visium spots (median of 4104 gene counts per spot; **Extended Data**
124 **Fig.1c**) were coloured by cluster identities and visualised in UMAP space, with

125 representation from all 6 patients in each cluster (**Fig.1c**). 11 high level clusters were
126 identified and annotated namely My1, My2 and My3 (Myeloid rich), B/Fib (cluster rich in B
127 and Fibroblast transcripts), TL (T lymphocyte rich), KC1 (Keratinocyte 1 rich), Fib
128 (Fibroblast 1 rich), KC2 (Keratinocyte 2 rich), B (B cell rich), and Endo (Endothelial cell
129 rich) and an uncharacterised cluster (mix) (**Fig. 1d,e**). Spatial mapping generated a coarse
130 transcriptomic map reflecting underlying tissue morphology (**Fig. 1f** and **Extended Data Fig.**
131 **1b,d**). The three myeloid rich clusters had distinct positioning and gene expression
132 signatures. My1 (*SELENOP*⁺) and My2 (*CCL18*⁺) were located in the papillary dermis near
133 the epidermal-dermal junction (herein referred to as “lesion core”), My1 also contained B
134 cells (*IGHA1*, *IGHG2*, *IGKC*) (**Supplementary Fig. 1a**). My1 and My2 were enriched for
135 mRNAs encoding i) S100 proteins (*S100A8*, *S100A9*) suggestive of neutrophils, monocytes
136 and DC⁴⁷; ii) metallothionein genes (*MT1H*, *MT1G*, *MT1X* and *MT2A*) and *SLC39A8*,
137 suggesting altered metal ion homeostasis; and iii) *CCL18*, a T cell chemoattractant ⁴⁸
138 (**Supplementary Fig. 1b**). My3 (*CHIT1*⁺) was associated with a T lymphocyte-rich cluster
139 (*CCL19*⁺) deeper in the dermis (**Extended Data Fig. 1d**). *IDO1* and *CD274* transcripts
140 mapped to the lesion core and to the T cell rich region (**Fig. 1g,h**, and **Supplementary Fig.**
141 **2a,b**) and to the My1, My2 and My3 clusters (**Fig. 1i**). My2 was also enriched for other
142 immune regulators including *SIGLEC10*⁴⁹, *VSIG4*⁵⁰ and *CD300E*⁵¹ (**Supplementary Fig.**
143 **1b**).

144

145 Using a publicly available scRNAseq dataset³⁸ and the Cell2Location⁵² prediction tool, we
146 projected estimated abundances of 40 cell types (**Extended Data Fig. 2**). Although some
147 interpatient heterogeneity was observed, macrophages (*FCGR2A*, *F13A1*, *NR4A1*, *NR4A2*,
148 *KLF4*), helper T cells (*CD4*, *IL7R*, *CD40LG*, *PTGER4*), regulatory T cells (*FOXP3*, *TIGIT*,
149 *BATF*, *CTLA4*), natural killer cells (*KLRD1*, *GZMB*, *PRF1*, *GZMB*, *NKG7*), and cytotoxic T

150 cells (*CD8A*, *CD8B*) were most highly represented. (**Extended Data Fig. 2a**). My1, My2
151 and My3 clusters contained Tc, Th, Treg and NK cells, myeloid DC (DC2; *CD68*, *NR4A1*,
152 *NR4A2*, *CLEC10A*, *FCGR2A*, *CD83^{low}*), ILC2 (*IL7R*, *PTGDR2*, *GATA3*), Macro1(*MARCO*,
153 *CD163*, *C1QB*, *FCGR2A*), Macro2, monocytes (*CD14*, *IL1B*) and ILC1/NK (*KLRB1*, *XCL1*,
154 *XCL2*, *TNFRSF18*, *TNFRSF11*, *FCER1G*, *KIT*) in differing proportions (**Extended Data Fig.**
155 **2b-1**). Although Ig transcripts were found in these clusters, formal identification of B cells /
156 plasma cells was not possible using the Reynolds et al reference data set³⁸.

157

158 **Mature dendritic cells express abundant *CD274* and *IDO1* mRNA**

159 To overcome limitations of cellular deconvolution, we next applied single cell spatial
160 transcriptomics. Using Nanostring CosMx⁵³, we analyzed 115,157 single cells from 20 fields
161 of view (FOVs) derived from four patients (**P3-P6**; **Extended Data Fig. 3a-e**)
162 (**Supplementary Table 1**) and identified 22 cell clusters (**Fig.2a** and **Extended Data Fig.**
163 **3f,g**). Cells with myeloid signatures were most abundant in the papillary dermis (**Fig. 2b**),
164 supporting our Visium analysis. We also identified T cells near the dermal and epidermal
165 boundary, flanked by fibroblasts and B cells in the lesion core. Deeper in the dermis, T cells
166 along with scattered macrophages were dominant (**Fig.2b**). The localisation of additional cell
167 populations is shown in **Extended Data Fig. 4a-d**. We next subclustered all myeloid cells
168 (mac, mac2, mDC, pDC, monocytes, and neutrophils) to obtain 13 sub-populations (**Fig. 2c,d**
169 and **Extended Data Fig. 4e,h**). When ranked by *CD274* and *IDO1* mRNA abundance
170 (**Extended Data Fig. 4i,j**), mature dendritic cell cluster DC3 was identified as having the
171 highest proportion of *IDO1^{hi} CD274^{hi}* cells. Smaller proportions of many other myeloid cell
172 populations also expressed these ICs. DC3 mapped to the lesion core and the deeper T cell
173 rich regions of the dermis (**Fig.2e**) and expressed mRNA for other immunoregulatory
174 molecules (*CD40* and *PDCD1LG2*; PD-L2; **Fig. 2d**).

175 ***CD274* and *IDO1* mRNA abundance correlates with distinct cytokines and chemokines**

176 To gain insights into the pathways leading to *IDO1* and PD-L1 expression, we first sought to
177 identify cytokine expression in niches where *CD274*⁺ and *IDO1*⁺ cells were abundant. Due to
178 the limited cytokine / chemokine coverage of the CosMx gene panel, we reverted for this
179 analysis to our Visium data. We classified Visium spots into four classes: *CD274*^{hi}*IDO1*^{lo}
180 (*CD274* spots), *CD274*^{lo}*IDO1*^{hi} (*IDO1* spots), *CD274*^{hi}*IDO1*^{hi} (*IDO1/CD274* spots) or
181 *CD274*^{lo} *IDO1*^{lo} (rest of the spots) and mapped their distributions and predicted cell type
182 abundances (**Fig. 3a,b** and **Extended Data Fig. 5a-d**). As compared to *CD274* spots,
183 *IDO1/CD274* spots and *IDO1* spots had a higher monocyte abundance and higher cytotoxic T
184 cell : helper T cell ratio. We performed differential expression analysis to identify cytokines,
185 chemokines, their receptors, and ICs that were significantly different across these classes
186 (**Extended Data Fig. 5e**) and observed four distinct patterns of gene expression (**Fig. 3c-k**
187 and **Extended Data Fig. 5f,g**). *CCL18*, *IL24*, *IL1B*, *TNFRSF6B*, *IFNGR2*, *CXCL9* and *IL32*
188 were highly expressed in *IDO1/CD274* spots and to a lesser degree in *IDO1* spots in the
189 lesion core, with *CXCL9* and *IL32* also found in the T cell rich hypodermis (**Fig. 3d-g**). The
190 homeostatic chemokines *CXCL12*⁵⁴ and *CXCL14*⁵⁵ showed a reciprocal distribution being
191 associated with spots lacking *IDO1* and *CD274* (**Fig. 3h,i**). *CCL19* (**Fig. 3j**), *CCR7*,
192 *CXCL13* and *LTB* (**Fig. 3k**) were most highly expressed in *CD274* spots in T cell rich areas.
193 Amongst anti-leishmanial effector and regulatory cytokines¹, *TNF* and *IFNG* were mostly
194 concentrated in the lesion core while *TGFBI* was widespread across the tissue (**Extended**
195 **Data Fig. 5h-j**).

196

197 **Neighbourhood analysis of *CD274* and *IDO1* expressing cells**

198 To identify cellular interactions contributing to the *CD274* and *IDO1* niches, we similarly
199 classified myeloid cells in our CosMx dataset into 4 classes by *IDO1* and *CD274* expression

200 **(Fig. 4a,b and Extended Data Fig.6a,b)**. $CCL18^+$ macrophages (*CCL18*, *MT2A*, *CD14*,
201 *SI00A9*, *C1QB*, *CD68*, *LYZ*) were the predominant cell type across all three classes (**Fig. 4c**
202 and **Extended Data 6a,b**). We then used Delaunay triangulation in Giotto to construct a pan
203 spatial network based on cell centroid physical distances⁵⁶. We observed that each cell had
204 4-8 close “neighbours” (**Extended Data Fig. 6c,d**). Using this framework, we assigned
205 $IDO1^+$ mye, $CD274^+$ mye and $IDO1^+/CD274^+$ mye cells as 'source' cells or as “both”
206 neighbour and source (**Fig.4d, e and Extended Data Fig.6e,f**) and visualised source-
207 neighbour or both-neighbour abundance using the UpSetR tool⁵⁷ (**Fig.4f and Extended Data**
208 **Fig. 6 g,h**). This analysis revealed a consistent neighbourhood composition, comprising other
209 $IDO1^+$ or $CD274^+$ myeloid cells, $CD274^+IDO1^-CCL18^+$ macrophages, CD8 memory T cells
210 and regulatory T cells (Tregs) (**Fig. 4g-i**). For orthogonal validation, we performed
211 immunostaining for PD-L1, IDO1, and CD8 proteins in biopsies where sufficient tissue was
212 available (n=23 SL-CL patients), demonstrating CD8⁺ T cells in close proximity to IDO1 and
213 PD-L1 positive cells (**Fig. 4j**). Employing bespoke image analysis pipelines, we created
214 image masks at distances of 25, 50, and 100 microns from $IDO1^+$, $PD-L1^+$ (**Extended Data**
215 **Fig. 6i,j**) and $IDO1^+PD-L1^+$ cells (**Fig. 4k**), revealing that the majority of CD8⁺ T cells were
216 located within 25 μ m of such cells and confirming them as immediate neighbours.
217
218 We then examined the phenotypes of source and neighbouring cells with respect to cytokines
219 and chemokines identified above as co-enriched in *CD274* and *IDO1* niches (**Fig. 3c**). *IL32*
220 expression was significantly higher in CD8⁺ T memory cells and Tregs whereas *CXCL9* and
221 *CCL18* were predominantly expressed by other myeloid cells including those that also
222 expressed *CD274* and *IDO1* (**Fig. 4l-n**). In contrast, *IL24*, *IFNGR2* and *IL1B* were primarily
223 expressed by $IDO1^+$ and $CD274^+$ and source myeloid cells (**Fig 4n-q**). Similar patterns were
224 observed for neighbours of *CD274* and *IDO1* single positive cells (**Extended Data Fig. 6k,l**).

225 Hence, in Sri Lankan CL lesions, CD8⁺ memory T cells and Tregs (**Extended Data Fig. 6m**)
226 represent the most common neighbours of CD274⁺ IDO1⁺ cells and are a major source of the
227 CD274⁻ and IDO1⁻ inducing cytokine IL-32. Since both IL32 β and IL32 γ isoforms can
228 induce either IDO1 or/and PD-L1 in macrophages^{58, 59, 60}, and IL-32 γ expression has been
229 reported in patients with *L. (V.) braziliensis* infection⁶¹, we investigated which isoform was
230 expressed in SL_CL lesions. Quantitative RT-PCR confirmed that IL32 γ and IL32 β were the
231 most highly upregulated isoforms in lesion compared to healthy skin (**Extended Data Fig.**
232 **7**).

233

234 **IL32 is a common spatial correlate of CD274 and IDO1 expression.**

235 Although differing mechanisms of immunopathology may occur across the leishmaniasis
236 disease spectrum, IDO1 and PD-L1 have been consistently identified in transcriptomic
237 studies^{32, 62, 63, 64, 65}. To assess whether the CD274 and IDO1 niche composition we
238 identified in SL_CL patients was also seen in other forms of dermal leishmaniasis, we
239 performed Visium analysis on biopsies from four Brazilian patients with *L. (V.) braziliensis*
240 CL (**Fig. 5a, b, Extended Data Fig. 8a, b and Supplementary Table 2**) and two patients
241 from India with *L. donovani* post kala-azar dermal leishmaniasis (PKDL) (**Fig. 5c,d,**
242 **Extended Data Fig. 8c, d and Supplementary Table 3**). Histologically, we observed a
243 diffuse cellular infiltrate in these samples (**Fig. 5b,d and Extended Data Fig. 8b,d**), and
244 CD274 and IDO1 expression showed similar patterns within the papillary dermis (**Fig. 5e,f**
245 and **Extended Data Fig. 8e-g**). Using the same analysis strategy (**Fig. 5g and Extended**
246 **Data Fig. 8h**), we found that IDO1^{hi} CD274^{hi} spots were restricted mainly to the upper
247 dermis (**Fig. 5h,i and Extended Data Fig. 8i, j**). IL32 and CXCL9 were strongly expressed
248 in all IDO1/ CD274 spots in both datasets along with other cytokines (**Extended Data Fig.**
249 **9a-f**). Based on the top 50 correlates (top 10 shown in **Extended Data Fig. 9g-j**), we

250 identified signatures associated with *IDO1* (*IL32*, *GBP5*, *GZMB*, *LYZ*, *SOD2*, *IFI30*, *FTH1*,
251 *GBP1*, *SRGN*, *CTSS*; **Fig. 5j**) and *CD274* (*IL32*, *LYZ*, *WARS*, *IFI30*, *FTH1*, *GBP1*, *FCER1G*;
252 **Fig. 5k**) expression across all three disease forms. A subset of 5 genes emerged as a core
253 correlate across all three datasets, namely *IL32*, *LYZ* (Lysozyme), *GBP1* (Guanylate-Binding
254 Protein 1), *IFI30* (lysosomal thiol reductase) and *FTH1* (Ferritin heavy chain 1).

255

256 **IL-32 is a predictive biomarker for rate of cure in Sri Lankan CL**

257 As IL-32 has been previously shown to induce IDO1 and PD-L1 expression and the latter has
258 been related to treatment outcome, we investigated the association between IL-32 expression
259 and treatment outcome (**Fig. 6**). Quantitative analysis of IL-32 staining in the dermis (n=25
260 SL_CL patients; **Fig. 6a** and **Supplementary Table 1**) allowed stratification into two patient
261 groups (IL-32^{hi} or IL-32^{lo}) based on geometric mean number of IL-32⁺ cells / mm² (**Fig. 6b**). IL-
262 32^{lo} patients were significantly more likely to cure early after treatment compared to IL-32^{hi}
263 patients (Log rank test, p=0.0025; **Fig. 6c**) with an estimated age- and sex- adjusted Cox
264 model hazard ratio of 3.5 (95% CI, 1.19 – 10.3, p= 0.023; **Fig. 6d**). Given that our
265 neighbourhood analysis above indicated a role for IL-32⁺ Treg cells in maintenance of the
266 IDO / PD-L1 niche, we stained tissue sections for IL-32 in combination with a marker of
267 Tregs (FoxP3; n=22 patients; **Fig. 6e**). Patients stratified based on FoxP3⁺ IL-32⁺ cell
268 abundance (**Fig. 6f**) did not show a significant difference in cure rate (**Fig. 6g,h**). In contrast,
269 when we conducted a similar analysis based on co-expression of IL-32 and CD8 α (n=25
270 patients; **Fig. 6i-l**) we found that patients with low abundance of CD8⁺IL-32⁺ cells were
271 significantly more likely to cure earlier (Log rank test, p=0.0051) with an age- and sex-adjusted
272 Cox model hazard ratio of 2.78 (95% CI, 1.093-7.5, p=0.044; **Fig. 6k**). Collectively, these
273 data strongly argue that IL-32⁺ CD8⁺ T cells are associated with the generation and / or

274 maintenance of IDO1 and PD-L1 niches during CL and in such a way indirectly serve to
275 restrain immune-dependent chemotherapy.

276

277 **Discussion**

278 Enrichment of cells expressing IDO1 and PD-L1 is a common feature of chronic
279 inflammatory diseases^{66, 67, 68, 69, 70} and cancer^{40, 71}, underscoring the role of myeloid-T cell
280 interactions in pathological tissue microenvironments. High-throughput spatial profiling
281 studies have revealed immunosuppressive niches in cancer tissue microenvironments
282 (TMEs), comprising IDO1- and PD-L1- expressing suppressive macrophages, CD8⁺ T cells
283 and regulatory T cells^{33, 66, 72}. Two studies also shed light on the regulators of IDO1 and PD-
284 L1 in the tumour microenvironment. One used multiplexed imaging to show IFN γ -dependent
285 increases in CD4⁺/CD8⁺ T cells in *ex vivo* “responder” tumour explants⁶⁶. The second used
286 limited protein/chemokine panels to characterize dysfunctional CD8⁺ T cells in melanoma-
287 associated tertiary lymphoid structures⁷³. In our current study of CL lesions, we applied i)
288 whole transcriptome-based spatial analysis to identify different cytokines and chemokines
289 associated with IDO1 and PD-L1 microenvironments, ii) a targeted subcellular 1000-plex
290 RNA panel to reveal cellular interactions at single cell resolution, and iii) validated our
291 results using quantitative immunohistochemistry.

292

293 Our study provides new insights into the immunopathology of human CL. First, we
294 identified myeloid cell-rich niches comprising mature dendritic cells (DC3) and *CCL18*⁺ M2-
295 like macrophages (*CCL18_mac*) in the papillary dermis that highly express *CD274* (PD-L1)
296 and *IDO1*. Second, neighbourhood analysis identified close interactions between
297 *CD274*⁺/*IDO1*⁺ myeloid cells, and CD8⁺ memory T cells and Tregs as well as with *IDO1*⁻
298 *CD274*⁻ *CCL18*⁺ macrophages. Third, we identified a molecular signature associated with

299 these niches (*CCL18*, *IL24*, *IL1B*, *TNFRSF6B*, *IFNGR2*, *CXCL9* and *IL32*) and their cellular
300 source. Finally, using other geographically and clinically diverse forms of dermal
301 leishmaniasis, we narrowed this signature to 5 common correlates of *IDO1* and *CD274* (*IL32*,
302 *LYZ*, *GBP1*, *IFI30* and *FTH1*). While both *GBP1*⁷⁴ and *FTH1*⁷⁵ have garnered interest as
303 therapeutic targets in cancer and inflammation, IL-32 emerged as a key factor produced by
304 CD8⁺ T memory and Treg cells in our study. High abundance of IL-32⁺CD8⁺ T cells
305 correlated with slower healing in Sri Lankan patients treated with sodium stibogluconate,
306 identifying it as a prognostic biomarker for treatment response in this form of leishmaniasis.
307 Hence, this study provides new insight into mechanisms supporting the generation of
308 immunosuppressive niches in CL lesions and reveals cell interactions and gene signatures
309 that may impact treatment response (as shown here) or disease natural history.

310

311 Myeloid cells play a central role in the immunobiology of leishmaniasis and have been
312 explored extensively in mouse models, with studies ranging from seminal studies of
313 migratory skin DCs⁷⁶ to the more recent identification of embryonic-derived CD206^{hi}
314 macrophages⁷⁷ and inflammatory monocytes⁷⁸ as preferred host cells for *L. major*. Myeloid
315 cell heterogeneity in the context of human leishmaniasis is much less well-understood and
316 our analysis formally demonstrates the complexity of the myeloid cell response in terms of
317 phenotypic heterogeneity and spatial organisation. We highlight two notable findings. First,
318 we find a substantial proportion of moDCs and DCs distributed between the lesion core and T
319 cell rich regions in the hypodermis. These DCs express *IDO1* and *CD274* supporting
320 previous observations that DCs with regulatory phenotype are expanded in chronic
321 inflammatory conditions and might contribute to immunosuppression^{38, 79}. Second, the lesion
322 core contains abundant CCL18-expressing macrophages and these account for a significant
323 fraction of all myeloid cells expressing *IDO1* and *CD274*. CCL18 produced by such

324 macrophages may recruit naïve T cells⁸⁰ and Tregs⁴⁸ to further augment an inhibitory niche.
325 In an analogous fashion, CCL18⁺ tumour associated macrophages (TAMs) promote
326 immunosuppression in cancer⁸¹. Furthermore, IDO1⁺ CD274⁺ CCL18⁺ macrophages express
327 *IL1B*, *IL24*, and *IFNGR2*. Given previous studies that indicate a role for IFNs in the induction
328 of PD-L1 and IDO1 in macrophages^{39,42} and for TNF in the induction of IL-24 and IL1B⁸²
329 these data are suggestive of macrophage activation by both IFN γ and TNF. This conclusion
330 is further supported by co-expression of *TNF* and *IFNG* in IDO1/ CD274 spots in the lesion
331 core, associated with T cell infiltration. Thus, in CL the regulation of IC expression appears
332 distinct from that recently described in the IFN γ -depleted core of tuberculosis granulomas³⁵.

333

334 In the tumour microenvironment, macrophages also foster a supportive environment for
335 malignant cell survival through coupled inhibition of apoptosis and compromised
336 immunosurveillance⁸³. For example, soluble decoy receptor 3 (*TNFRSF6B*; DcR3) inhibits
337 apoptosis by binding to LIGHT⁸⁴ or Fas-Fas ligand⁸⁵ complexes on T cells and, through its
338 interaction with heparin sulphate proteoglycans, can also promote epigenetic reprogramming
339 and macrophage polarisation to an M2 phenotype⁸⁶. We observed that DcR3 was also
340 expressed in the IDO1 / PD-L1 niches found in CL lesions, suggesting that further
341 exploration of the role of DcR3 in leishmaniasis is warranted.

342

343 A central finding of this study was the identification of IL-32 as a previously unknown core
344 component of the IDO1 / PD-L1 niche in multiple forms of dermal leishmaniasis. IL-32 is a
345 complex and still poorly understood cytokine that can be produced by multiple cell lineages
346 (reviewed in⁸⁷). Studies of IL-32 are hampered by multiple isoforms, each with distinct
347 biological effects and the lack of IL-32 in rodents⁸⁸. IL-32 γ is the longest isoform with an
348 intact signal peptide and is secreted. Both IL-32 β and IL-32 γ are proinflammatory, with the

349 beta isoform being the most abundant and the gamma isoform being the most biologically
350 active⁸⁹. IL-32 has been mooted as a biomarker in a variety of skin conditions including
351 atopic dermatitis and melanoma⁹⁰. It has been ascribed a pro-inflammatory and host
352 protective role in tuberculosis and in models of colitis and arthritis based on the use of
353 hu*IL32* transgenic mouse models. A role for IL-32 in leishmaniasis has also been previously
354 suggested, based on similar transgenic mouse models and the enhanced expression of IL-32
355 in lesion biopsies from patients with *L. braziliensis* infection^{61, 88}. However, none of these
356 published studies has addressed IL-32 expression in a spatially resolved manner. We
357 confirmed high expression of both IL32 γ and IL32 β in our patient biopsies, identified the
358 cellular sources of IL-32 in the lesion, spatially mapped IL-32 and demonstrated that IL-32⁺
359 CD8⁺T cells represent a key molecular and cellular component of the IDO / PD-L1 niche. In
360 keeping with other facets of IL-32 biology, our data imply a microenvironmentally-controlled
361 immunoregulatory role for IL-32 in human CL.

362

363 Despite the differences in pathologies between SL_CL, *L. braziliensis* CL and PKDL, our
364 analysis revealed a core gene signature (*IL32*, *LYZ*, *GBP1*, *IFI30* and *FTH1*) associated with
365 *IDO1*⁺ and *CD274*⁺ expression. IL-32 expression is commonly associated with T cells and
366 especially Tregs, though we demonstrate that this cytokine can also be expressed at low
367 frequency in some myeloid cells in CL lesions. In contrast, *LYZ* (lysozyme), *GBP1*
368 (Guanylate-Binding Protein 1, an interferon inducible GTPase), *IFI30* (Interferon inducible
369 lysosomal thiol reductase) and *FTH1* (Ferritin heavy chain 1) are all prototypic myeloid cell
370 markers. This mixed cellular composition was reflected by deconvolution of cell abundances
371 in our Visium data sets, wherein we observed a predominance of Treg, CD8⁺ T cells,
372 macrophages and DCs. Further studies are required to determine whether other members of
373 this core signature contribute to shaping the immunoregulatory environment in leishmaniasis.

374

375 In our previous study of SL_CL patients, we identified elevated expression of IDO1 and PD-
376 L1 in pre-treatment biopsies and demonstrated that an early reduction in PD-L1 after
377 treatment onset was predictive of rate of cure³². Although providing a mechanistic basis for
378 how ICs might restrict the efficacy of T cell-dependent chemotherapy, this study did not
379 provide insights into the cellular or molecular mechanisms ultimately responsible for driving
380 IC expression. The results presented here now allow us to propose a model for the regulation
381 of ICs in CL, rooted in spatial interaction mapping and validated through multiple orthogonal
382 approaches: 1) CCL18⁺ macrophages recruit IL-32⁺ CD8⁺ T cells and IL-32⁺ Tregs into a
383 myeloid cell niche; 2) IL-32⁺ CD8⁺ T cells and IL-32⁺ Tregs induce expression of ICs in
384 DCs and macrophages by paracrine signalling through the as-yet-uncharacterised IL-32
385 receptor, 3) IDO1⁺PD-L1⁺ myeloid cells respond to T cell derived cytokines (IFN γ , TNF)
386 and secrete additional M2-polarising cytokines such as IL-24 and IL-1 β , and 4) IDO1 and
387 PD-L1 expressed by DCs and macrophages in the niche promote loss of effector T cell
388 function, through tryptophan starvation and PD-1 signalling respectively (see Graphical
389 Abstract).

390

391 The study has some limitations. Clinical sampling was limited on ethical grounds to two
392 biopsies, so we have been unable to evaluate expression levels of IDO1 or PD-L1 at disease
393 resolution. Although not statistically significant, patients with low abundance of IL-
394 32⁺FoxP3⁺ Tregs also showed a trend towards faster healing, a result that deserves further
395 exploration with larger sample sizes. Logistical constraints associated with studying patients
396 in an endemic country setting impacted our ability to perform phenotypic and / or functional
397 characterisation of cells isolated from lesion biopsies. Consequently, our cell deconvolution
398 approaches may not reflect all cell phenotypes present in CL lesions due to the use of non-

399 matched scRNA-seq data sets. As we were unable to isolate lesional mononuclear cells for
400 in vitro analysis, we cannot formally address the question of T cell antigen specificity or
401 extend our analysis of myeloid cells ex vivo. Finally, we have limited our current analysis to
402 exploring cell-extrinsic regulation of IDO1 and PD-L1 expression by myeloid cells. Ongoing
403 studies are exploring how the regulation of ICs on myeloid cells is regulated in a cell-intrinsic
404 manner following intracellular parasitism by *Leishmania* (Dey et al, in preparation).

405

406 In summary, using spatially resolved high dimensional analysis of lesion biopsies, we have
407 mapped the molecular and spatial niches associated with IDO1 and PD-L1 expressing
408 myeloid cells in CL lesions and identified IL-32-expressing CD8⁺T cells as prognostic of rate
409 of cure. Given the commonality of niche composition across multiple forms of dermal
410 leishmaniasis, it is tempting to speculate that our observations may also contribute to local
411 immunoregulation and treatment response in multiple forms of dermal leishmaniasis and that
412 similar regulation of the IDO1/ PD-L1 niche may occur during other infectious and non-
413 infectious diseases.

414

415

416 **Methods**

417 **Samples: SL2 cohort, BR cohort and IN cohort.**

418 **Study design**

419 *Sri Lanka:* The study design for the Sri Lankan cohort was initially published as part of the
420 validation cohort details in Dey et al, 2021³². Briefly, individuals who provided written
421 informed consent and exhibited clinically highly suspected CL lesions were enrolled. On day
422 0, punch biopsies were collected and intralesional sodium stibogluconate (SSG) treatment
423 was administered. Biopsies were processed into formalin-fixed and embedded in paraffin

424 (FFPE) format and then shipped to the University of York (UoY) for subsequent
425 immunological studies described here. These enrolled patients were then monitored for up to
426 6 months to assess complete clinical cure, and given weekly intralesional SSG injections. Of
427 these, 24/25 patients had achieved complete clinical cure by 6 months, and 1/25 patients at
428 6.5 months. Out of the 25 patients in this cohort, 23/25 patient sections were included in the
429 neighbourhood image analysis aimed at identifying neighbours of IDO1 and PD-L1 in stained
430 sections; two were excluded due to insufficient material in the blocks. For including samples
431 for 10x Visium analysis, these 23 patients were further screened for the presence of parasites
432 by using an RNA probe against *Amastin* to detect parasites in 5µ thick sections as described
433 previously³². 6/23 were *Amastin*⁺ and were included for Visium spatial analysis (P1-P6).
434 Furthermore, out of the 6 samples included for Visium analysis, only four samples could be
435 included in the CosMx analysis due to the availability of sufficient material in the blocks for
436 follow up studies.

437

438 *Brazil*: Patient cohort from Brazil involved 20 patients that agreed to participate by signing
439 the informed consent Form. Patients were diagnosed on the basis of positive polymerase
440 chain reaction and/or indirect immunofluorescence and/or ELISA directed to *Leishmania*.
441 Depending on the size and location of the lesion and the clinical condition of the patients,
442 treatment was done with systemic pentavalent antimonials (Glucantime) for 20 days; or
443 intralesional pentavalent antimonials (Glucantime) with one application per week for 4
444 weeks; or liposomal amphotericin B for 10 days. Biopsy samples of the lesion were collected
445 on day 0 when the diagnosis was established and patients were followed up after treatment
446 for 6 months to assess clinical cure. To understand IDO1 and CD274 microenvironments in
447 healing and non-healing chronic skin *L.(V)b.* lesions, 20 patient samples were screened for
448 double positivity against diagnostic PCR and ELISA (12/20) and were then stratified on the

449 basis of visual treatment score at 3 months; healed if visual score=0 at 3 months and not
450 healed if visual score >0 at 3 months. Of 12 samples, only 2 patients had healing score>0 at 3
451 months and were included in the study. 2 patients with visual score=0 at 3 months with
452 comparable age, lesion size and lesion duration were then selected from the bigger cohort
453 (12) to include a total of 4 samples that were processed through 10x Visium.

454

455 *India:* The initial diagnosis was based on clinical features suggestive of PKDL (presence of
456 papules, nodules and/or hypopigmented macular lesions), a prior history of VL, rK-39
457 positivity, and/or if they resided in an area endemic for VL. In general, cases with
458 hypopigmented patches were considered as macular PKDL, whereas cases with an assortment
459 of papules, nodules, plaques, and/or macules were termed as polymorphic PKDL. Based on
460 these criteria, individuals who were willing and provided written informed consent were
461 enrolled for this study. The patients were examined by a clinician, clinical history recorded,
462 and biological samples (blood and punch biopsy) collected. Subsequently, the diagnosis was
463 confirmed by qPCR⁹¹. 2 samples with typical histopathology of PKDL lesions and
464 comparable RNA quality were chosen. These two patients were enrolled between November
465 2019 and August 2021. 5u thick sections were cut and processed through 10x Visium.

466 *Lesion characteristics and diagnostic methods.* For patients recruited in Sri Lanka and
467 included in the study, lesions were dry nodular ulcerative (n=8), dry ulcers (n=6), dry
468 ulcerated plaques (n=5), wet ulcers (n=2), papular satellite lesions (n=2), nodule with satellite
469 lesions (n=1), ulcerated plaque with satellite lesions (n=1) with mean ulcerated area of 51.13
470 mm² (\pm SD, 81.1) and mean area of induration of 1430.2 (\pm SD, 1966.9). In addition to
471 clinical assessment, CL was diagnosed by slit skin smears (SSS) (18/23) and PCR (23/23).

472 Amongst Indian patients, the polymorphic case presented with lesions (papules and nodules)
473 on the face, specifically on the forehead, nose and chin while the macular patient had a hypo

474 pigmented patch on the back. In case of polymorphic cases, the biopsy was collected from a
475 nodule, whereas in macular PKDL, it was from an area of hypopigmentation. In addition to
476 clinical examination by a dermatologist, PKDL was also confirmed by qPCR. Both patients
477 gave a previous history of VL, for which they had received sodium antimony gluconate
478 For patients recruited in Brazil and included in the study, lesions were showed wet ulcers in
479 the lower (3/4) or upper limbs (1/4) with mean ulcerated area of 2475mm² (\pm SD, 2148). The
480 diagnosis was confirmed by PCR specific for *Viannia* subgenus (4/4), indirect
481 immunofluorescence (2/4) and ELISA (4/4).

482

483 *Slit skin smears (SSS)*: For Sri Lankan cohort only, tissue scrapings from a 3mm superficial
484 nick from the active edge of the lesions were used to prepare smears on slides, stained with
485 Giemsa and examined under oil immersion microscopy for the presence of amastigotes.
486 Parasite density was graded from 0 to 6+ according to WHO guidelines for VL⁹²: 0—no
487 parasites per 1000 high power fields (HPF: x 1000 magnification); 1+: 1–10 parasites per
488 1000 HPFs; 2+: 1–10 parasites per 100 HPFs; 3+: 1–10 parasites per 10 HPFs; 4+: 1–10
489 parasites per HPF; 5+: 10–100 parasites per HPF; and 6+: > 100 parasites per HPF.
490 Amastigote density for each Sri Lankan sample is outlined in Supplementary Table 1.

491

492 *Punch Biopsy*: A 3mm diameter full thickness punch biopsy was taken from the edge or
493 centre of the lesion under local anaesthesia, transported in formol saline and then fixed in
494 paraffin blocks and used for H&E or FISH + IF and transcriptome analysis studies.

495 Simultaneously an 2mm diameter punch biopsy was taken for PCR.

496

497 *PCR*: DNA extraction was performed from 2mm excision biopsy and was used as an input
498 material for diagnostic PCR for *Leishmania* positivity as previously described³². In Sri

499 Lanka, LITSR/L5.8S specific primers were used that amplifies a 320 bp fragment of ITS1
 500 region of *Leishmania* genus-specific DNA. In Brazil, kDNA specific primers were used that
 501 amplify 750 bp kinetoplastid DNA of *Leishmania* subgenus *Viannia*⁹³. In India, DNA
 502 extraction was performed using manufacturer’s instructions using QIAamp DNA mini kit,
 503 Qiagen, Hilden, Germany from a skin biopsy collected in phosphate- buffered saline (20 mM,
 504 pH 7.4) and eluted in 50 µL of DNA elution buffer. Real-time PCR was performed using
 505 specific primers for kinetoplast minicircle gene, using 1ul of DNA as input material and 400
 506 nM of each primer. DNA isolated from a *Leishmania donovani* strain MHOM/IN/1983/AG83
 507 served as the positive control while negative controls used were DNA from a healthy donor
 508 (no amplification), and a reaction mixture with water instead of template DNA (no-template
 509 control)⁹¹.
 510

Diagnostic PCR primers for <i>L. don</i> CL	LITSR (forward) 5’- CTGGATCATTTCGGATG-3	L 5.8S (reverse) 5’- TGATACCACTTATCGCACTT-3’
Diagnostic PCR primers for <i>L. (V)</i> kDNA	B1. 5’-GGGGTTGGTGTAATATAGTG G-3’	B2. 5’-CTAATTGTGCACGGGGAGG- 3’
Diagnostic PCR	Forward: 5’- CTTTTCTGGTCCCTCCGGGTAGG-	reverse: 5’- CCACCCGGCCCTATTTTACACC

primers for <i>L.</i> <i>don.</i> PKDL	3'	AA-3'
---	----	-------

511

512 *ELISA and Indirect immunofluorescence reaction:* In Brazil, all sera were tested for
513 immunoglobulin G (IgG) antibodies at 1:50 dilution in the ELISA using whole *L. major*-like
514 parasite lysate (ELISA–*L. major*-like) as previously described⁹⁴. For both antigens, the cut-
515 off point was determined using a receiver operating characteristic (ROC) curve. The
516 reactivity index (RI) was calculated for each sample by dividing the sample absorbance value
517 by the cut-off. Samples were considered positive if the RI value was ≥ 1 . The
518 spectrophotometric reading of each well was performed at 450 nm using a Multiskan GO
519 instrument (Thermo Scientific, Finland). The IIF test was performed on the slides, containing
520 the suspension of fixed promastigotes of *Leishmania* (*Leishmania major*-like
521 promastigotes/MHOM/BR/71/49) as previously described⁹⁵. Then the slide was observed in
522 the fluorescence microscope, with the objective of 250 \times .

523

524 **Sectioning**

525 FFPE blocks were placed on cool plate prior to sectioning and 5 μ m sections were cut and
526 serial sections were placed onto Superfrost glass slides for CosMx or H&E or 10x Visium
527 onto the capture area making sure that all layers of the skin were represented in the cut
528 section.

529

530 **Low-resolution spatial transcriptomic mapping of CL lesions using 10x Visium**

531 Visium gene expression slides were processed using the Visium Spatial gene expression
532 reagent kits for FFPE as per recommended protocols. In brief, slides were deparaffinised in
533 Xylene twice for 10 minutes each and then stained for hematoxylin and eosin. Stained slides
534 were coverslipped and imaged on an Axioscan slide scanner. Post imaging cover slips were
535 removed, slides were placed in a Visium cassette and were de-crosslinked. Human probes
536 were added overnight after which they were extended and released. Library preparation was
537 done based on manufacturer's instructions and sequenced using a NovaSeq 6000. Raw
538 FASTQ files were aligned to the GRCh38 genome
539 (https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.40/) and the
540 Spaceranger_1.3.0 (10x) count was used to generate UMI counts per spatial barcode. Raw
541 counts were normalised and analysed further. Code used for analysis and figures is described
542 under "Code Availability".

543

544 **Integration and clustering of 10x Visium data**

545 We used Seurat (Seurat_4.3.0) package in R 4.2.3 to analyse spot matrices. Normalisation
546 across spots was performed using SCTransform(). We used FindIntegrationAnchors()
547 function to find anchor spots across samples and then used IntegrateData() to integrate all
548 samples based on 3000 features as identified upon data integration. 30 Principal Components
549 derived using 3000 features in the integrated assay were used as an input for clustering
550 Visium spots with a resolution of 0.5 using FindClusters() and UMAP was used to visualise
551 clustering in two-dimensional space. Differential gene expression (DE) between clusters was
552 calculated first by running PrepSCTFindMarkers() to normalise for median genes as a proxy
553 for sequencing depth. FindAllMarkers() was then used to find DE genes using a minimum
554 setting for log2fold change as 0.25 with genes that were expressed in a minimum of 25%
555 spots (min.pct=0.25). P-value of DE genes was based on a two-tailed Wilcoxon Rank Sum

556 test. List of DE markers from each cluster was then fed into CellMesh⁹⁶ (
557 https://uncurl.cs.washington.edu/db_query) using probabilistic model to identify probable cell
558 types expressed in cluster spots. Clusters were then annotated based on most abundant cell
559 type expressed and then plotted onto each tissue image using SpatialDimPlot function from
560 Seurat and required DE genes were visualised using EnhancedVolcano package in R. Spatial
561 maps of *IDO1* and *CD274* (PD-L1) were generated using SpatialPlot() function. For
562 comparison across My1, My2 and My3, matrices were extracted from Seurat and plotted in
563 Graphpad for violin plots.

564

565 **Deconvolution of Visium spots to identify immune cell abundance**

566 We utilized Cell2location⁵² to deconvolve cell type composition per 55µm Visium spatial
567 spots. The hyperparameters used were N_cells_per_location=30 and detection_alpha=20,
568 using the dataset Reynolds *et al*³⁸ (accession number: E-MTAB-8142;
569 www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8142.) as a skin single-cell reference
570 dataset. First, we estimated reference cell type signatures by training a negative binomial
571 regression model for 1,000 epochs retaining the cell-type annotations from Reynolds *et al*.
572 We then used the reference signature model to deconvolute the spatial data using the
573 aforementioned hyperparameters, training the Cell2location model for 30,000 epochs. We
574 inferred cell abundance per spatial spot using the 5% quantile values of the posterior
575 distribution, where the model has high confidence as per the tool's manual. Predicted
576 abundances were used to infer compositions in My1, My2, My3, *IDO1*, *CD274* and *IDO1*/
577 *CD274* spots.

578

579 **Identifying molecular networks associated with CD274 and IDO1 expression**

580 To look for correlation between *IDO1* and *CD274* across all spots, all spots covered under the
581 tissue from Sri Lankan patients (n=6) were visualised using FeatureScatter() function in
582 Seurat. Thresholds on the scatterplot were put below or equal to median of total expression of
583 *IDO1* (1.2) and *CD274* (0.6). All spots were then annotated as *IDO1* spots ($IDO1 > 1.1$ &
584 $CD274 < 0.5$) or *CD274* spots ($IDO1 < 1.1$ & $CD274 > 0.5$) or *IDO1/ CD274* spots ($IDO1 >$
585 1.1 & $CD274 > 0.5$) or rest of the spots ($IDO1 < 1.1$ & $CD274 < 0.5$). DE genes were then
586 graphed as line plot in GraphPad 9.3.1 whereas the rest were plotted as dot plots using
587 DotPlot function in Seurat in R. A similar strategy was followed for patients from Brazil
588 (n=4) presenting with CL lesions and patients from India (n=2) presenting with PKDL
589 lesions.

590

591 We performed a pairwise correlation analysis of all genes in the dataset with *IDO1* and
592 *CD274* using the cor.test() function from the R stats package (version 4.1.1), employing
593 Spearman's ranked correlation method. A significance threshold of 0.05 was applied to
594 identify significant correlations. Subsequently, the top 50 correlated genes from each dataset,
595 which included Visium gene expression data from 6 Sri Lankan CL patients, 4 CL patients
596 from Brazil, and 2 PKDL patients from India, were extracted. These gene sets were then
597 subjected to comparison using Venny 2.0
598 (<https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html>) to identify common correlates of
599 *IDO1* and *CD274* across these three datasets.

600

601 **Single cell resolution spatial transcriptomic mapping of CL lesions using CosMx**
602 **molecular imager.**

603 For CosMx, a single slide containing sections from skin lesions of 4 patients from SL2
604 patients were sent to Nanostring Translational Services lab, Seattle under Technology Access

605 Program (TAP). CosMx Human Universal Cell Characterization RNA Panel (1000-plex) was
606 used to analyse gene expression at subcellular level. Morphology of the tissue was visualised
607 by staining for B2M/CD298, PanCK, OPB (for parasite), CD3 antibodies and DAPI post
608 hybridization of probes. The methods for sample processing and cell segmentation are
609 described in CosMx methods study⁵³. A total of 20 Fields of View (FOVs) were created
610 across 4 patient samples. Expression matrix of transcripts along with their x, y and z
611 coordinates, cell ID, metadata, FOV positions were loaded onto Giotto package to create an
612 integrated giotto object in R⁵⁶ and then filtered based on minimum expression threshold of
613 1;> 5 features/cell and > 5 cells expressing one feature. Expression matrix was normalised
614 using standard method of data normalisation for total library size followed by scaling for a
615 factor of 6000, log normalisation and z scoring of data by genes and/or cells. Expression
616 values were then regressed for total sum of feature expression and number of features
617 expressed per cell to account for batch to batch variation.

618

619 **Clustering and cell type annotation of CosMx data**

620 UMAP dimension reduction algorithm was used for individual cell data presentation based on
621 CosMx SMI gene expression profiles. For a further QC, total count numbers and slide ID
622 were projected onto UMAP space to assess data quality and no total count-based clustering
623 bias was found. Coarse cell typing was done using nb_clust, a semi-supervised cell clustering
624 (negative binomial) algorithm developed by NanoString team resulting in detection of 16
625 immune cell types using single cell data sets. 6 unsupervised cell clusters (KC1, KC2, KC3,
626 plasmablast2, fib2 and mac2) were also identified and were labelled on the most enriched cell
627 type based on CellMesh reference database⁹⁶. DE between clusters was done using
628 findMarkers_one_vs_all from Giotto package using Gini coefficient Followed by
629 plotMetaDataHeatmap from Giotto package to plot heatmap of gene expression. Cell ID and

630 expression matrix of all cells were then imported into Seurat package and subclustered to
631 identify further subtypes. Myeloid cells (cluster IDs: mac, mac2, mDC, neutrophil, pDC,
632 monocyte, mast) were subclustered into 13 subtypes that were annotated on gene expression
633 and projected onto UMAP space. 12% of total cells that showed abundance of border
634 transcripts from nearby cells due to faulty assignment of transcripts were subsetted out.
635 ImageDimplot from Seurat and SpatPlot from Giotto were used to map cell types onto space.

636

637 **Neighbourhood analysis of *CD274* and *IDO1* expressing cells**

638 *IDO1* and *CD274* values from all myeloid cells were correlated and thresholds were placed
639 that showed clear assignment of all myeloid cells into *IDO1*mye⁺ (*IDO1* > 3 and *CD274* <3),
640 *CD274*mye⁺ (*IDO1* < 3 and *CD274* >3), *IDO1*⁺/*CD274*mye⁺ (*IDO1* > 3 and *CD274* >3) and
641 were annotated as such. SpatPlot2D from Giotto package was used to map cell types onto
642 space. To create a network that revealed spatial relationships and interactions among
643 individual cells, we first used plotStatDelaunayNetwork function from Giotto to estimate
644 distance between each cell and its neighbours by calculating pairwise distances between cells
645 and identifying statistically significant connections. We estimated that each cell had 4-6
646 nearest neighbours. We then used createSpatialNetwork from Giotto using k =4 to limit the
647 number of neighbours to 4.

648

649 To investigate cellular interactions within the spatial network, we first created an interaction
650 map for *IDO1*mye⁺, *CD274*mye⁺, *IDO1*⁺/*CD274*mye⁺ with 4 immediate neighbour cells
651 using annotateSpatialNetwork function from Giotto. To create spatial plots illustrating these
652 interactions, we first used findNetworkNeighbors function to identify these neighbours.
653 Spatial plots were then generated using SpatPlot2D function to visualize the cellular
654 interactions. Cells were color-coded based on their classification as “source” (specified cell;

655 IDO1mye⁺ or CD274mye⁺ or IDO1⁺/CD274mye⁺) or "neighbour" (amongst 4-6 immediate
656 neighbours of specified cell) or "both" (a neighbour and a source cell) or "others" (not a
657 neighbour to specified cell nor a source cell). Cell IDs and cell type annotation of these cells
658 were then imported into UpsetR shiny app ⁵⁷ (<https://gehlenborglab.shinyapps.io/upsetr/>) to
659 estimate the most abundant neighbour combination to IDO1mye⁺ or CD274mye⁺ or
660 IDO1⁺/CD274mye⁺ cells and into a worksheet to estimate composition of these populations
661 and graphed in GraphPad. For additional validation, neighbour combinations were also
662 checked in an excel sheet to tally neighbour combination numbers. To look at spatial maps of
663 specific interactions, an additional metadata column with information about interacting and
664 non-interacting cell types of the selected cell-cell interaction was created and visualised using
665 spatPlot from Giotto.

666

667 To look at cytokine and chemokine expression patterns in source and neighbouring cells, cell
668 IDs of IDO1mye⁺ or CD274mye⁺ or IDO1⁺/CD274mye⁺ source cells and top 5 neighbours
669 (CCL18_{mac}, Treg, IDO1mye⁺, CD274mye⁺, T CD8 memory) were subsetted and violin
670 plots, heatmaps (using Giotto in R) or bar charts (in GraphPad Prism 10) were plotted to look
671 at cytokine expression in these cells.

672

673 **Immunostaining**

674 FFPE sections were obtained from 23 or 25 Sri Lankan patients, with 23 FFPE patient lesion
675 blocks used for the IDO1, PD-L1, and CD8 staining set due to material constraints. For
676 FoxP3 staining set, only 22 sections were analysed due to sample detachment during
677 processing. The staining protocol involved following steps: heat fixation at 60°C to ensure
678 sample adherence, followed by two rounds of 5-minute deparaffinization in histo clear/xylene
679 at room temperature (RT). Subsequent steps included equilibration in 95% ethanol for 3

680 minutes, 70% ethanol for another 3 minutes, and hydration in distilled water for 3 minutes.

681 Antigen retrieval was achieved through a 15-minute high-pressure treatment with citrate

682 buffer (pH 6.0), followed by a 25-minute standing period at RT. After two 5-minute washes

683 with wash buffer (PBS + 0.5% BSA w/v), tissue sections were delineated with a wax pen.

684 The procedure continued with blocking (PBS + 0.1% Triton X-100 v/v + 5% Normal donkey

685 serum v/v + 5% Normal goat serum v/v + 1% BSA w/v) for 30 minutes, overnight primary

686 antibody incubation with IDO1 (1:200) and PD-L1 (1:500) at 4°C in the fridge, and three 5-

687 minute washes the next day. Secondary antibody staining for 30-45 minutes at RT employed

688 CF750 Donkey Anti-Rabbit IgG CFTM 750 and Goat anti-Mouse Dy650 at a 1:500

689 concentration. Sections were then incubated with CD8-AF594 for 2h at room temperature.

690 After three more buffer washes, YOYO-1 at 0.2uM concentration was added for 30 minutes

691 in wash buffer. Three final wash buffer washes were performed before applying Prolong

692 Gold mounting media and coverslips.

693

694 For the IL-32 CD8 set and IL-32 FoxP3, the same protocol was followed with minor

695 adjustments. Antigen retrieval utilized TE buffer (10mM Tris Base, 1mM EDTA, 0.05%

696 Tween 20, pH 9.0), while pre-primary blocking consisted of PBS + 0.1% Triton X-100 v/v +

697 5% Normal goat serum v/v + 1% BSA w/v. The slides were incubated with IL-32 (1:400) and

698 CD8a or FoxP3 overnight at 4°C and were developed with goat anti-rabbit Dylight 650 and

699 Goat anti-mouse AF555 F(ab)₂ at a 1:500 concentration, respectively. Notably, no second

700 blocking step was carried out for IL-32 CD8/ FoxP3 set. Detailed antibody information,

701 including catalogue numbers and dilutions, can be found in the reporting summary.

702

703 **Image acquisition and analysis.**

704 Whole tissue section images were acquired using Zeiss AxioScan.Z1 slide scanner at 20x
705 magnification. Identical exposure times and threshold settings were used for each channel on
706 all sections of similar experiments. Whole section images of IDO1, PD-L1, CD8/ FoxP3 and
707 IL-32 were quantitated using StrataQuest Analysis Software (TissueGnostics, v
708 7.0.1.178). We first segmented nuclei based on YOYO1 staining and then created cell
709 polygons over grey images of CD8 (outside), PD-L1(outside and inside) and IDO1 (outside
710 and inside) using nuclei mask. A cut off was applied on IDO1/PDL-1 mean intensity based
711 on visual inspection of the tissue to delineate IDO1/ PD-L1 ^{+/+} cells. We then created coded
712 images for each of the markers and used proximity maps function in Strataquest 7.178
713 (<https://tissuegnostics.com/products/contextual-image-analysis/strataquest>) to generate
714 distance maps at 25, 50 and 100 µm from IDO1, PD-L1 or IDO1 PD-L1 double positive
715 polygons and then detected CD8 masks within these proximity areas

716

717 For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1
718 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring
719 mask with interior and exterior radius of -0.20 and +0.20 µm). As FoxP3 staining was
720 nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask.
721 Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to
722 ensure no false positives were included. The same cut-off was applied for all samples.
723 Scattergram was generated with IL-32 and CD8/ FoxP3 mean intensities and gated on
724 positive IL-32 and CD8/ FoxP3 cells. Upper right quadrant of these scattergrams gave data
725 for IL-32⁺ CD8⁺/ IL-32⁺ FoxP3⁺ cells.

726

727 **Multivariate Cox proportional hazard model**

728 For correlation of IL-32 with cure rates, total IL-32⁺ CD8⁺ IL-32⁺ and FoxP3⁺ IL-32⁺ cells
729 per mm² of tissue section per patient (n=22-25) was computed from image analysis. Patients
730 were then stratified on geomean of total IL-32 (6969.37), CD8⁺ IL-32⁺ (2800.9), FoxP3⁺ IL-
731 32⁺ (544.0) expression into IL-32 high (>6969.37; n=14) or low (<6969.37; n=11) and
732 CD8⁺IL-32⁺ high (>2800.9; n=13) or low (<2800.9; n=12) and FoxP3⁺IL-32⁺ high (>544.0;
733 n=16) or low (<544; n=6). These values were then imported in R and Kaplan Meier survival
734 (cure) curves were generated for IL-32 or CD8⁺IL-32⁺ or FoxP3⁺ IL-32⁺ expression groups
735 using the survfit function, and survival differences were assessed with the survdiff function
736 from survminer, survival, ggplot2 packages. We then constructed multivariate hazard models
737 adjusted for participant age and sex, employing the survival and survminer packages. The
738 statistical scores were derived from Wald's statistic value, followed by estimation of hazard
739 ratios, which were visualized on forest plots.

740

741 **RNA isolation and qPCR**

742 The total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) patient samples
743 using RNeasy FFPE Kit (Qiagen) as per manufacturer's protocol. Briefly, 2 x 10 μ m sections
744 were cut from each block and put into deparaffinization buffer (Qiagen). Sample lysis was
745 done using Proteinase K digestion for 15 minutes. After lysis, samples were incubated at
746 80°C for 15 minutes followed by 15 minutes of DNase treatment. Finally, concentrated RNA
747 was purified using RNeasy MinElute spin columns, and eluted in a volume of 14–30 μ l.
748 Purity and concentration of extracted RNAs were checked and quantified by reading at 260
749 and 280 nm in a NanoDrop spectrophotometer (Thermo Fisher). Next, 50ng total RNA was
750 reverse transcribed using Superscript IV first strand cDNA Synthesis Kit (Invitrogen) and
751 random hexamers (Invitrogen) according to manufacturer's protocol.

752 qRT-PCR was performed with Fast SYBR Green Master Mix (ThermoFisher) and primers
753 using a StepOnePlus Real-Time PCR System (ThermoFisher). cDNA extracted from LPS
754 (100 ng/ul for 4 hours) stimulated PMA (100 ng/ul) differentiated THP-1 cells line was used
755 as a positive control to optimise primers⁹⁷. All primers were optimised by serially diluting
756 LPS stimulated THP-1 cDNA. Relative transcript levels were determined using the $\Delta\Delta C_t$
757 method using GAPDH/ ACTB as a housekeeping gene and healthy skin. All reactions were
758 performed in duplicates. Primer list used in the study is given in the table below.
759
760

<i>IL32alpha</i>	Forward 5'-GCTGGAGGACGACTTCAAAGA-3'
<i>IL32alpha</i>	Reverse 5'-GGGCTCCGTAGGACTTGTC-3'
<i>IL32beta</i>	Forward 5'-GAAGACTGCGTGCAGAAGGT-3'
<i>IL32beta</i>	Reverse 5'-CTTTCTATGGCCTGGTGCAT-3'
<i>IL32gamma</i>	Forward 5'-AGGCCCGAATGGTAATGCT-3'
<i>IL32gamma</i>	Reverse 5'-CCACAGTGTCTCAGTGTGTCACA-3'
<i>IL32delta</i>	Forward 5'-TCTGTCTCTCTCGGGTCCTCTCT-3'
<i>IL32delta</i>	Reverse 5'-TGTCTCCAGGTAGCCCTCTTTG-3'

761

762

763 **Acknowledgements**

764 The authors thank all patients and their families who took part in this study. We also thank all
765 members of the Kaye laboratory at Hull York Medical School, University of York for their

766 useful comments and suggestions on this project, Robert Nica and Simina Laslau at the
767 technical department at Tissue Gnostics for help with Strataquest, TAP team at Nanostring,
768 Seattle specially Emily Killingbeck, Youngmi Kim and Claire Williams for initial support
769 with CosMx and the Biosciences Technology Facility at University of York for support
770 throughout the project. Biorender.com was used to generate the graphical abstract.

771

772 **Author contributions**

773 N.S.D., S.D. and P.M.K. conceived the study; N.S.D. and S.D. did the analysis; N.S.D., S.D.,
774 and N.B. conducted experiments; N.S.D and P.M.K wrote the manuscript; P.M.K, S.R.,
775 M.C., and H.G. secured funding; all other co-authors provided materials or clinical
776 assessments for the study and reviewed the manuscript.

777

778 **Data availability**

779 The sequencing data reported in this paper have been deposited in the GEO database under
780 the accession code GEO: TBC. The processed sequencing data is available as Rds files on
781 Zenodo: <https://doi.org/10.5281/zenodo.10402126>. Additional data (**Supplementary Table**
782 **4**) related to the figures is also available on figshare (DOI:
783 <https://doi.org/10.6084/m9.figshare.24803511>).

784

785 **Code availability**

786 Code used for analysis (including that for generating Figs from Visium seq data and CosMx
787 imaging data) in this study is available at <https://github.com/NidhiSDey/leish-ME>

788

789 **Ethics statements**

790 **Institutional review board statement**

791 Written informed consent including for lesion photographs was obtained from participants
792 under a protocol for the project titled “Towards a global research network for the molecular
793 pathological stratification of leishmaniasis” approved by Ethical Review Committee of the
794 Faculty of Medical Sciences, University of Jayewardenepura (ref: 780/13 & 52/17), Ethics
795 Committee of the Faculdade de Medicina, Universidade de Sao Paulo- CAAE
796 39964520.8.0000.0068, Institutional Ethics Committee of School of Tropical Medicine,
797 Kolkata and Institute of Post Graduate Medical Education and Research, Kolkata
798 (IPGME&R/IEC/2019/208) and the Biology Ethics Committee (ref: PK201805), Department
799 of Biology, University of York. This study was conducted according to the Declaration of
800 Helsinki (2013).

801

802 **Inclusion and Ethics statement**

803 We affirm that our research upholds the highest ethical standards and contributes to the
804 advancement of immunological science in an inclusive and responsible manner.

805

806 **Funding**

807 This work was supported by funding from the UK Medical Research Council / UK Aid
808 Global Challenges Research Fund (MR/P024661/1 to PMK, SR, HG, and MC), a Wellcome
809 Trust Senior Investigator Award (WT104726 and WT224290 to PMK) and Fundac o de
810 Amparo   Pesquisa do Estado de S o Paulo (2018/14398-0) and fellowship (2019/25393-1)
811 to HG.


812

813 **Competing interests**

814 All authors declare no competing interests.

815 **Figures and Extended Figures**

Fig.1: 10x Visium guided spatial transcriptomics reveals organised domains in CL lesions from Sri Lanka




816

817 **Fig. 1: Spatial transcriptomics identifies spatial domains in *L. donovani* CL lesions.**

818 **a**, Patient P3 showing lesion macroscopic features. **b**, Left, histology of P3 shows dense
 819 dermal infiltrate (Hematoxylin and eosin; H&E; Bar 500µm). Right, Higher magnification of
 820 site of parasitism; top, H&E and bottom, anti-*Leishmania* OPB staining. Bar 10 µm. Parasites
 821 indicated in H&E by yellow arrow. **c**, UMAP projection of Visium spots from patients P1-P6
 822 coloured by patient ID. **d**, as (**c**) but clustered, coloured and labelled by gene expression. **e**,
 823 Heatmap showing the top 10 genes enriched in each cluster. **f**, Spatial map for patient P3
 824 coloured by clusters identified in (**d**). **g-h**, Spatial feature plots for P3 showing normalised
 825 values of *CD274* (**g**) and *IDO1* (**h**) **i**, *IDO1* and *CD274* violin plots for My1-3 clusters for P1-
 826 6 (red dotted line, mean; black dotted lines, IC range) p-values for group mean ranks
 827 compared by Kruskal-Wallis one-way test.

828

Extended Data Fig. 1: Patient photographs, histological staining of sections and spatial maps of spot clusters from Sri Lanka




829

830 **Extended Data Fig 1: Spatial transcriptomics identifies spatial domains in *Leishmania***
 831 ***donovani* infected CL skin.**

832 **a**, Photographs of patients P1, P2, P4, P5 and P6. **b**, H&E images of patients described in **(a)**
 833 showing dense cellular infiltrate. **c**, Violin plot showing overall gene counts across all
 834 patients. Red line shows median gene count across all samples (n=6) **d**, Spatial maps for
 835 patients described in **(a)** coloured by clusters identified in Fig.1f. **e-k**, Spatial feature plot for
 836 P3 overlaid on H&E showing normalised gene expression of top genes expressed in each
 837 cluster: *KRT14*, *CCL18*, *JCHAIN*, *COL1A1*, *CCL19*, *CHIT1* and *SPARCL1* (left panels)
 838 and spatial maps of respective clusters (right panels).

839

Extended Data Fig. 2 :Decomposition of cell types in 10x Visium spots




840

841 **Extended Data Fig. 2: Deconvolution of cell types in 10x Visium spots**

842 **a**, Bar plot showing 5th quantile predicted cell abundances per spot for P1-P6. Black line
 843 represents median value, bar indicates interquartile range. **b**, Donut representation of
 844 predicted average abundance for the 10 most abundant cell types in My1-3 spots. Total
 845 (inside each donut) depicts average number of cells predicted across My1-3 spots. **c-l**,
 846 Predicted abundance of cell types in lesion core and T-rich regions (shown for patient P3).

847

Fig. 2: Single cell imaging of cutaneous lesions from Sri Lanka




848

849

850 **Fig. 2: Single-cell transcriptomic imaging of cutaneous lesions from Sri Lanka**

851 **a,b**, Single cell spatial mapping of CL lesions. **a**, UMAP representation of single cell data
 852 from 4 patients coloured by cell type **b**, single cell representation of P3 lesion biopsy
 853 generated by stitching individual FOVs. Boxes 1-4 provide higher magnification views of
 854 selected regions of interest. **c**. Same as **(a)** but for sub-clustered myeloid cells only. **d**, Dot
 855 plot showing gene expression across the sub-clustered myeloid cell types in **(c)**. **e**,
 856 localisation of DC3, moDC2 and on patient P3 with representative magnified regions of
 857 interest.




858

859 **Extended Data Fig. 3: FOV positions, patient annotations, gene expression and cell**
 860 **number per cluster**

861 **a**, H&E images for patients P3-P6 showing FOV analysed using Nanostring CosMx. Bar 500
 862 μm **b**, Bar plots showing total cell numbers probed per patient. **c**, Cells were visualised in
 863 UMAP space and coloured by patient identity. **d-e**, Bar plots showing number of genes (**d**)
 864 and negative probes (**e**) detected per cell in the same dataset. **f**, Heat map showing top genes
 865 expressed by the identified cell types in all 4 patients. **g**, Stacked bar plot showing total cell
 866 counts across all patients for each population.

867



868

869


Extended Data Fig. 4: Spatial maps of cell types onto P3 section

870

a-h, Single-cell spatial mapping of indicated cell types for patient P3. **i-j**, Violin plots showing *IDO1* (**a**) and *CD274* (**b**) expression across DC3, moDC2, cDC2, infl_mac1 and DC1 cell types (n=4 patients). Average expression of *IDO1* and *CD274* was computed across all clusters and cell types that showed upper quartile expression were plotted.

874

Fig. 3: 10x Genomics Visium: 50 μm neighbourhoods of *IDO1*⁺ and *CD274*⁺ cells



875

876

Fig. 3: 55 μm neighbourhoods of *IDO1*⁺ and *CD274*⁺ cells

877

878

879

880

881

882

883

884


884

885

885

a, Scatterplot of *IDO1* and *CD274* normalised gene expression for all 55um Visium spots (for patients P3-P6). Thresholds were drawn at $x=1.1$ and $y = 0.5$ to classify spots as IDO1, CD274, IDO1/ CD274 or rest of the spots. **b**. Representative spatial plot coloured by spot class in (a) shown for P3. Insets identify lesion core and dermal T cell rich regions as inferred from Visium and CosMx datasets. **c**, Cytokine, chemokine, or receptor abundance by IDO1 and PD-L1 expression class described in (a) across $n=4$ patients. **d-k**, Spatial feature plots for cytokines, chemokines, and interleukins from (c) in lesion core and T cell rich area for patient P3.

Extended Data Fig. 5: Characterisation of *IDO1*, *CD274* and *IDO1/CD274* rich spots




886

887

888 **Extended Data Fig. 5: Characterisation of *IDO1*, *CD274* and *IDO1/CD274* rich spots**

889 **a**, Spatial feature plots for cytokines, chemokines and interleukins for patients P1, P2, P4-P6.
 890 **b-d**, Bar plot showing 5th quantile top 20 predicted cell abundances for IDO and PD-L1
 891 classes defined in (a) across all patient lesions (P1-P6). Black line represents median value,
 892 bar indicates interquartile range. **e**, Differential gene expression for selected genes across the
 893 grouping from (a). Log2Fold change cut off was set at 0.3 and p value >0.01. Data shown is
 894 from all 6 patients. **f-g**, Spatial feature plots for additional selected genes in lesion core and T
 895 cell rich area for patient P3.

Fig. 4: Phenotype of *IDO1*⁺ *CD274*⁺ myeloid cells and neighbours



896


897 **Fig. 4: Phenotype of *IDO1*⁺ *CD274*⁺ myeloid cells and neighbours**

898 **a**, Scatter plot of *CD274* and *IDO1* expression on myeloid cells in CosMx dataset. Thresholds
 899 at $y=3$ and $x=3$ were used to classify cells as single or double positive for *IDO1* and *CD274*
 900 ($n=4$ patients; P3-P6). **b**, Spatial plot for P3 coloured by class defined in (a). **c**, Pie chart of
 901 *IDO1*⁺ *CD274*⁺ cells by myeloid cell subset **d**, Cartoon representation of neighbourhood
 902 analysis (see M&M for details). **e**, Spatial map of *IDO1*⁺ *CD274*⁺ as “source” or “both”
 903 shown with neighbours. **f**, UpsetR bar plot of cell types classed as neighbours of *IDO1*⁺/
 904 *CD274*⁺ cells. Top 15 neighbour combinations are shown from 2418 source neighbour
 905 pairs. Connecting lines under the bar plot show neighbour combinations. Vertical bars
 906 represent total numbers of each combination while the horizontal plots indicate the total
 907 count of cell types as neighbours irrespective of the combination. **g-i**, Representative FOV
 908 showing spatial plots of *IDO1*⁺ *CD274*⁺ cells (pink) interacting with CD8 mem (red
 909 dots, **g**), Treg (magenta, **h**) and CCL18_mac (blue in **i**). Other cells not in neighbour
 910 combinations are depicted with an “oth_” prefix below figure **j**, Immunohistochemistry
 911 showing expression of *IDO1*, PD-L1 and CD8A protein expression. **k**, Quantitative image
 912 analysis of (**j**) from $n=23$ patients. Left panel shows imaging masks in shades of grey at 25,
 913 50 and 100 μm diameter from *IDO1*⁺ PD-L1⁺ cells. Right panel shows proportions of CD8⁺
 914 cells by distance from *IDO1*⁺ PD-L1⁺ double positive cell. Friedman’s one-way test with

915 Dunn's adjustment for multiple comparisons. Adjusted p-values are given. **l-q**, Box and
916 whisker plots showing minimum and maximum expression of *IL32* (**l**), *CXCL9* (**m**), *CCL18*
917 (**n**), *IL24* (**o**), *IFNGR2* (**p**) and *IL1B* (**q**) in top 5 neighbours from (**f**). One-way Kruskal
918 Wallis test. Mean (+) and median (vertical line) are indicated inside bars. Dunn's test
919 corrected for multiple comparisons. Adjusted p -values are given.

920


Extended Data Fig. 6: Phenotype and neighbours of $IDO1^+$, $CD274^+$ myeloid cells



921 **Extended Data Figure 6: Phenotype and neighbours of $IDO1^+$ and $CD274^+$ myeloid cells**

922 **a-b**, Pie chart for $IDO1mye^+$ (**a**) and $CD274mye^+$ (**b**) cells by myeloid subset (n=4 patients).
 923 **c**, Box and whiskers plots showing the cellular distances when a Delauney network is created
 924 for up to 22 immediate neighbours. Data for n=4 patients as in (a,b). **d**, Bar plot to show
 925 number of cells with between 3-22 immediate neighbours. **e, f**. Spatial plot of single cells for
 926 P3 coloured with “source” or “both” being either $IDO1mye^+$ (**e**) or $CD274mye^+$ (**f**). **g-h**,
 927 UpsetR plots for $IDO1mye^+$ (**g**) or $CD274mye^+$ (**h**) cells. 15 most frequent heterotypic
 928 interactions are shown from n= 5370 $IDO1mye^+$ and n=4,308 $CD274mye^+$ -neighbour source
 929 pairs, respectively. Connecting lines under the bar plot show neighbour combinations. We
 930 have also provided all the possible neighbour combinations in the source data file
 931 (**Supplementary Table 4**). Vertical bars represent total numbers of each combination while
 932 the horizontal plots indicate the total count of cell types as neighbours irrespective of the
 933 combination. **i-j**, Quantitative image analysis (n=23 patients) depicting proportions of $CD8^+$
 934 cells (yellow) present within 25,50, 100 μm and $>100 \mu m$ distance (left panels) from $IDO1^+$
 935 (**i**) and $PD-L1^+$ (**j**) cells. Cyan and red cell masks are drawn over $IDO1$ and $PD-L1$ positive
 936 cells respectively. Friedman’s one-way test with Dunn’s adjustment was applied for multiple
 937 comparisons. Adjusted p-value are given. **k-l**, Violin plots showing expression of *CCL18*,
 938 *IL24*, *IL1B*, *IFNGR2*, *CXCL9*, *IL32*, *TNFSF14* and *FASLG* in the top 5 neighbours of
 939 $IDO1mye^+$ (**i**), and $CD274mye^+$ (**j**) cells (n=4 patients). **m**, Heat map showing phenotype of
 940 T CD8 memory and Treg cells. Scale shows gini coefficient z scores (n=4 patients).

Extended Data Fig. 7: Expression of *IL32* isoforms in CL lesions



941

942


943

944 **Extended Data Fig. 7: Isoforms of *IL32* in CL patients**

945 **a**, Fold change of *IL32* α , β , γ and δ isoforms with respect to GAPDH and healthy skin in Sri
946 Lankan CL patients (n=2) and *L.(V.) braziliensis* CL patients. Bars show mean +/- standard
947 deviation.

948

Fig. 5 IDO1 CD274 niches in different dermal variants of leishmaniasis



949


950

951 **Fig. 5: IDO1 and CD274 niches in different dermal variants of leishmaniasis**

952

953 **a**, CL lesion caused by *L. braziliensis* in patient Lb_P1 from Brazil. **b**, H&E images of a 5µm
 954 section from (a) showing dense cell infiltration in the dermis. **c**, Polymorphic PKDL lesion
 955 caused by *L. donovani* in patient PKDL_P1 from India. **d**, H&E image of (c). **e-f**, Spatial
 956 plots showing the gene expression for *IDO1* and *CD274* on Lb_P1 (e) and PKDL_P1 (f). **g**,
 957 Scatter plot showing *CD274* and *IDO1* expression in all spots from *L. b* infected CL skin
 958 lesions (n=4). Thresholds at y=0.2 and x=0.5 used to classify spots. **h**, Spatial plot for *L. b*
 959 patients coloured by class as in (g). **i**, Spatial plot of IDO1 and PD-L1 classes for PKDL
 960 patients (n=2) derived from Extended Data Fig. 8h. **j-k**, Venn diagrams indicating overlap
 961 amongst top 50 genes per disease correlating with *IDO1* (**j**) and *CD274* (**k**).

Extended Data Fig. 8: *IDO1* and *CD274* microenvironments in *L.b* CL and *L.don* PKDL lesions



962


963 **Extended Data Fig. 8: *IDO1*⁺ and *CD274*⁺ microenvironments in *L. braziliensis* and *L.***
 964 ***donovani* infected CL and PKDL lesions respectively.**

965 **a**, CL lesions caused by *L. braziliensis*. Images for patients *L.b*_P2-P4. **b**, Matched H&E
 966 images of 5µm sections of lesions in (a). Mild inflammatory infiltrate and extensive fibrosis
 967 was seen in *L.b*_P2. **c-d**, Macular PKDL lesion caused by *L. donovani*. Image for patient
 968 PKDL_P2 (c) and corresponding histology shown in an H&E image (d). **e-f**, Spatial plots
 969 showing gene expression for *IDO1* (e) and *CD274* (f) for patients *L. b*_P2-P4. P2 showed
 970 very limited expression of *IDO1* and *CD274* with no overlap between the two expression
 971 patterns. **g**, Spatial plots showing the gene expression of *IDO1* (c) and *CD274* (d) for macular
 972 *L. don* PKDL_P2. **h**, Scatter plot showing *CD274* and *IDO1* expression across all spots from
 973 *L. don* PKDL_P1 and P2, with thresholds at y=0.2 and x=0.2. **i-j**, Spatial plots coloured by
 974 class for *L.b*_P2-4 (i) and PKDL_P2 (j).

975

976

Extended Data Fig. 9: Phenotyping *IDO1* and *CD274* microenvironments in *L.b* CL and *L.don* PKDL lesions



977


978

979 **Extended Data Fig. 9: Phenotyping *IDO1*⁺ and *CD274*⁺ microenvironments in *L.***
 980 ***braziliensis* CL and *L. donovani* PKDL and lesions.**

981 **a**, Dot plot showing differentially expressed cytokines, chemokines, interleukins, TNF and
 982 interfeon related and immune checkpoint markers between *IDO1* and *CD274* classes in *L.b.*
 983 CL patients (n=4; a) and PKDL patients (n=2, b). Cut off was p<0.05, Log2Fold = 0.25. **c-f**,
 984 Spatial plots showing gene expression for *CXCL9* and *IL32* in *L.b*_P1 and PKDL_ P1. **g-j**,
 985 Genes correlating with *IDO1* (**g,i**), and *CD274* (**h, j**) from all *L. b.* CL patients (g,h) and
 986 PKDL patients (i-j). Pearson's correlation coefficients are plotted in decreasing order
 987 (p<0.05).

988

Fig. 6: Lesional IL-32 expression is prognostic of cure rate in Sri Lanka



989

990

991 **Fig. 6 Lesion IL-32⁺ T cells are prognostic for rate of cure following treatment for CL in**
 992 **Sri Lanka**

993 **a**, IL-32 protein expression in Sri Lankan CL. **b**, Stratification of 25 patients based on
 994 geomean density of dermal IL-32⁺ cells (low, n=11, High, n=14). Horizontal bars indicate
 995 median value. **** p-value <0.0001 (Two-tailed Mann Whitney test). **c**, Kaplan Meier plot
 996 showing treatment response rate for IL-32 Low and High groups. Shaded area indicates 95%
 997 CI. p-value for Log rank (Mantel-Cox) test is shown. **d**, Forest plot of Cox proportional
 998 hazard model for IL-32⁺ low vs. IL-32⁺ high (reference), adjusted for age and sex. Hazard
 999 ratio (HR; 95% CI) and p value for each covariate is shown. **e-h**. same as (a-d) for IL-32⁺
 1000 FoxP3⁺ cells (n=22 patients) **i-l**, same as (a-d) for IL-32⁺CD8α⁺ cells (n=25 patients). Scale
 1001 bar in (a), (e), and (i) is 100 μm.

1002 **References**

- 1003 1. Scott, P. & Novais, F.O. Cutaneous leishmaniasis: immune responses in protection and
1004 pathogenesis. *Nat Rev Immunol* **16**, 581-592 (2016).
- 1005 2. Heyde, S. *et al.* CD11c-expressing Ly6C+CCR2+ monocytes constitute a reservoir for efficient
1006 Leishmania proliferation and cell-to-cell transmission. *PLoS Pathog* **14**, e1007374 (2018).
- 1007 3. Costa-da-Silva, A.C. *et al.* Immune Responses in Leishmaniasis: An Overview. *Trop Med Infect*
1008 *Dis* **7** (2022).
- 1009 4. Samant, M., Sahu, U., Pandey, S.C. & Khare, P. Role of Cytokines in Experimental and Human
1010 Visceral Leishmaniasis. *Front Cell Infect Microbiol* **11**, 624009 (2021).
- 1011 5. Bogdan, C. Macrophages as host, effector and immunoregulatory cells in leishmaniasis:
1012 Impact of tissue micro-environment and metabolism. *Cytokine X* **2**, 100041 (2020).
- 1013 6. Novais, F.O. & Scott, P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the
1014 ugly. *Semin Immunopathol* **37**, 251-259 (2015).
- 1015 7. Lecoeur, H., Prina, E., Gutierrez-Sanchez, M. & Spath, G.F. Going ballistic: Leishmania nuclear
1016 subversion of host cell plasticity. *Trends Parasitol* **38**, 205-216 (2022).
- 1017 8. Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania
1018 major in mice. *Nat Rev Immunol* **2**, 845-858 (2002).
- 1019 9. Tomiotto-Pellissier, F. *et al.* Macrophage Polarization in Leishmaniasis: Broadening Horizons.
1020 *Front Immunol* **9**, 2529 (2018).
- 1021 10. Ajdary, S., Alimohammadian, M.H., Eslami, M.B., Kemp, K. & Kharazmi, A. Comparison of the
1022 immune profile of nonhealing cutaneous Leishmaniasis patients with those with active
1023 lesions and those who have recovered from infection. *Infect Immun* **68**, 1760-1764 (2000).
- 1024 11. Manamperi, N.H. *et al.* In situ immunopathological changes in cutaneous leishmaniasis due
1025 to Leishmania donovani. *Parasite Immunol* **39** (2017).
- 1026 12. Montes de Oca, M. *et al.* Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-
1027 Mediated Tissue Pathology. *PLoS Pathog* **12**, e1005398 (2016).
- 1028 13. Katara, G.K., Ansari, N.A., Verma, S., Ramesh, V. & Salotra, P. Foxp3 and IL-10 expression
1029 correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis
1030 (PKDL) patients. *PLoS Negl Trop Dis* **5**, e1171 (2011).
- 1031 14. Bourreau, E., Prevot, G., Gardon, J., Pradinaud, R. & Launois, P. High intralesional interleukin-
1032 10 messenger RNA expression in localized cutaneous leishmaniasis is associated with
1033 unresponsiveness to treatment. *J Infect Dis* **184**, 1628-1630 (2001).
- 1034 15. Amorim, C.F. *et al.* Variable gene expression and parasite load predict treatment outcome in
1035 cutaneous leishmaniasis. *Sci Transl Med* **11** (2019).
- 1036 16. de Freitas, E.S.R. & von Stebut, E. Unraveling the Role of Immune Checkpoints in
1037 Leishmaniasis. *Front Immunol* **12**, 620144 (2021).
- 1038 17. Wykes, M.N. & Lewin, S.R. Immune checkpoint blockade in infectious diseases. *Nat Rev*
1039 *Immunol* **18**, 91-104 (2018).
- 1040 18. Paluch, C., Santos, A.M., Anzilotti, C., Cornall, R.J. & Davis, S.J. Immune Checkpoints as
1041 Therapeutic Targets in Autoimmunity. *Front Immunol* **9**, 2306 (2018).

- 1042 19. He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. *Cell Res* **30**, 660-1043 669 (2020).
- 1044 20. Carlin, J.M., Borden, E.C., Sondel, P.M. & Byrne, G.I. Interferon-induced indoleamine 2,3-1045 dioxxygenase activity in human mononuclear phagocytes. *J Leukoc Biol* **45**, 29-34 (1989).
- 1046 21. Popov, A. & Schultze, J.L. IDO-expressing regulatory dendritic cells in cancer and chronic1047 infection. *J Mol Med (Berl)* **86**, 145-160 (2008).
- 1048 22. Merlo, L.M.F., Peng, W. & Mandik-Nayak, L. Impact of IDO1 and IDO2 on the B Cell Immune1049 Response. *Front Immunol* **13**, 886225 (2022).
- 1050 23. Munn, D.H. *et al.* Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J1051 Exp Med* **189**, 1363-1372 (1999).
- 1052 24. Munn, D.H. *et al.* Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells1053 in tumor-draining lymph nodes. *J Clin Invest* **114**, 280-290 (2004).
- 1054 25. Fallarino, F. *et al.* The combined effects of tryptophan starvation and tryptophan catabolites1055 down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.1056 *J Immunol* **176**, 6752-6761 (2006).
- 1057 26. Huang, X., Zhang, F., Wang, X. & Liu, K. The Role of Indoleamine 2, 3-Dioxygenase 1 in1058 Regulating Tumor Microenvironment. *Cancers (Basel)* **14** (2022).
- 1059 27. Makala, L.H. *et al.* Leishmania major attenuates host immunity by stimulating local1060 indoleamine 2,3-dioxygenase expression. *J Infect Dis* **203**, 715-725 (2011).
- 1061 28. Lu, D. *et al.* Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated1062 Macrophages. *J Immunol Res* **2019**, 1919082 (2019).
- 1063 29. Ludovini, V. *et al.* High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated1064 with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. *Genes (Basel)*1065 **12** (2021).
- 1066 30. Della Corte, C.M. *et al.* Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic1067 strategy in NSCLC. *J Transl Med* **20**, 541 (2022).
- 1068 31. Kjeldsen, J.W. *et al.* A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in1069 combination with nivolumab in metastatic melanoma. *Nat Med* **27**, 2212-2223 (2021).
- 1070 32. Dey, N.S. *et al.* Early reduction in PD-L1 expression predicts faster treatment response in1071 human cutaneous leishmaniasis. *J Clin Invest* **131** (2021).
- 1072 33. Keren, L. *et al.* A Structured Tumor-Immune Microenvironment in Triple Negative Breast1073 Cancer Revealed by Multiplexed Ion Beam Imaging. *Cell* **174**, 1373-1387 e1319 (2018).
- 1074 34. Schalper, K.A. *et al.* Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in1075 Human Lung Cancer. *Clin Cancer Res* **23**, 370-378 (2017).
- 1076 35. McCaffrey, E.F. *et al.* The immunoregulatory landscape of human tuberculosis granulomas.1077 *Nat Immunol* **23**, 318-329 (2022).
- 1078 36. Lima, H.R. *et al.* Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to1079 Control Disease Progression. *Front Immunol* **8**, 1724 (2017).
- 1080 37. Gulati, N., Suarez-Farinas, M., Correa da Rosa, J. & Krueger, J.G. Psoriasis is characterized by1081 deficient negative immune regulation compared to transient delayed-type hypersensitivity1082 reactions. *F1000Res* **4**, 149 (2015).

- 1083 38. Reynolds, G. *et al.* Developmental cell programs are co-opted in inflammatory skin disease.
1084 *Science* **371** (2021).
- 1085 39. Pallotta, M.T. *et al.* Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an
1086 eclectic immunoregulatory enzyme. *FEBS J* **289**, 6099-6118 (2022).
- 1087 40. Liu, M. *et al.* Targeting the IDO1 pathway in cancer: from bench to bedside. *J Hematol Oncol*
1088 **11**, 100 (2018).
- 1089 41. Shklovskaya, E. & Rizos, H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The
1090 Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. *Int J Mol Sci*
1091 **21** (2020).
- 1092 42. Chen, S. *et al.* Mechanisms regulating PD-L1 expression on tumor and immune cells. *J*
1093 *Immunother Cancer* **7**, 305 (2019).
- 1094 43. da Fonseca-Martins, A.M. *et al.* Leishmania Parasites Drive PD-L1 Expression in Mice and
1095 Human Neutrophils With Suppressor Capacity. *Front Immunol* **12**, 598943 (2021).
- 1096 44. Donovan, M.J. *et al.* Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of
1097 human dendritic cells. *Parasite Immunol* **34**, 464-472 (2012).
- 1098 45. Hofmeyer, K.A., Jeon, H. & Zang, X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-
1099 induced cytotoxic T lymphocyte exhaustion. *J Biomed Biotechnol* **2011**, 451694 (2011).
- 1100 46. Barth, H. & Raghuraman, S. Persistent infectious diseases say - IDO. Role of indoleamine-2,3-
1101 dioxygenase in disease pathogenesis and implications for therapy. *Crit Rev Microbiol* **40**,
1102 360-368 (2014).
- 1103 47. Xia, C., Braunstein, Z., Toomey, A.C., Zhong, J. & Rao, X. S100 Proteins As an Important
1104 Regulator of Macrophage Inflammation. *Front Immunol* **8**, 1908 (2017).
- 1105 48. Chenivesse, C. *et al.* Pulmonary CCL18 recruits human regulatory T cells. *J Immunol* **189**, 128-
1106 137 (2012).
- 1107 49. Barkal, A.A. *et al.* CD24 signalling through macrophage Siglec-10 is a target for cancer
1108 immunotherapy. *Nature* **572**, 392-396 (2019).
- 1109 50. Vogt, L. *et al.* VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. *J*
1110 *Clin Invest* **116**, 2817-2826 (2006).
- 1111 51. Coletta, S. *et al.* The immune receptor CD300e negatively regulates T cell activation by
1112 impairing the STAT1-dependent antigen presentation. *Sci Rep* **10**, 16501 (2020).
- 1113 52. Kleshchevnikov, V. *et al.* Cell2location maps fine-grained cell types in spatial transcriptomics.
1114 *Nat Biotechnol* **40**, 661-671 (2022).
- 1115 53. He, S. *et al.* High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by
1116 spatial molecular imaging. *Nat Biotechnol* **40**, 1794-1806 (2022).
- 1117 54. Cambier, S., Gouwy, M. & Proost, P. The chemokines CXCL8 and CXCL12: molecular and
1118 functional properties, role in disease and efforts towards pharmacological intervention. *Cell*
1119 *Mol Immunol* **20**, 217-251 (2023).
- 1120
- 1121 55. Frederick, M.J. *et al.* In vivo expression of the novel CXC chemokine BRAK in normal and
1122 cancerous human tissue. *Am J Pathol* **156**, 1937-1950 (2000).

- 1123 56. Dries, R. *et al.* Giotto: a toolbox for integrative analysis and visualization of spatial expression
1124 data. *Genome Biol* **22**, 78 (2021).
- 1125 57. Lex, A., Gehlenborg, N., Strobel, H., Vuillemot, R. & Pfister, H. UpSet: Visualization of
1126 Intersecting Sets. *IEEE Trans Vis Comput Graph* **20**, 1983-1992 (2014).
- 1127 58. Liu, Y. *et al.* Myeloma-derived IL-32gamma induced PD-L1 expression in macrophages
1128 facilitates immune escape via the PFKFB3-JAK1 axis. *Oncoimmunology* **11**, 2057837 (2022).
- 1129 59. Ohmatsu, H. *et al.* IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and
1130 indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: Relevance to mycosis fungoides
1131 progression. *Oncoimmunology* **6**, e1181237 (2017).
- 1132 60. Yan, H. *et al.* Multiple myeloma cell-derived IL-32gamma increases the immunosuppressive
1133 function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.
1134 *Cancer Lett* **446**, 38-48 (2019).
- 1135 61. Galdino, H., Jr. *et al.* Interleukin 32gamma (IL-32gamma) is highly expressed in cutaneous
1136 and mucosal lesions of American Tegumentary Leishmaniasis patients: association with
1137 tumor necrosis factor (TNF) and IL-10. *BMC Infect Dis* **14**, 249 (2014).
- 1138 62. Farias Amorim, C. *et al.* Localized skin inflammation during cutaneous leishmaniasis drives a
1139 chronic, systemic IFN-gamma signature. *PLoS Negl Trop Dis* **15**, e0009321 (2021).
- 1140 63. Kong, F. *et al.* Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a
1141 Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease
1142 Promoting Phenotype. *PLoS Pathog* **13**, e1006165 (2017).
- 1143 64. Rodrigues, V. *et al.* Transcriptional Analysis of Human Skin Lesions Identifies Tryptophan-2,3-
1144 Deoxygenase as a Restriction Factor for Cutaneous Leishmania. *Front Cell Infect Microbiol* **9**,
1145 338 (2019).
- 1146 65. Christensen, S.M. *et al.* Meta-transcriptome Profiling of the Human-Leishmania braziliensis
1147 Cutaneous Lesion. *PLoS Negl Trop Dis* **10**, e0004992 (2016).
- 1148 66. Shekarian, T. *et al.* Immunotherapy of glioblastoma explants induces interferon-gamma
1149 responses and spatial immune cell rearrangements in tumor center, but not periphery. *Sci*
1150 *Adv* **8**, eabn9440 (2022).
- 1151 67. Shin, E.C., Sung, P.S. & Park, S.H. Immune responses and immunopathology in acute and
1152 chronic viral hepatitis. *Nat Rev Immunol* **16**, 509-523 (2016).
- 1153 68. Chevalier, M.F. & Weiss, L. The split personality of regulatory T cells in HIV infection. *Blood*
1154 **121**, 29-37 (2013).
- 1155 69. Winheim, E. *et al.* Impaired function and delayed regeneration of dendritic cells in COVID-19.
1156 *PLoS Pathog* **17**, e1009742 (2021).
- 1157 70. Pett, S.L. *et al.* Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor
1158 Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.
1159 *Open Forum Infect Dis* **5**, ofx228 (2018).
- 1160 71. Tang, Q. *et al.* The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in
1161 human cancers. *Front Immunol* **13**, 964442 (2022).
- 1162 72. Danenberg, E. *et al.* Breast tumor microenvironment structures are associated with genomic
1163 features and clinical outcome. *Nat Genet* **54**, 660-669 (2022).

- 1164 73. Hoch, T. *et al.* Multiplexed imaging mass cytometry of the chemokine milieu in melanoma
1165 characterizes features of the response to immunotherapy. *Sci Immunol* **7**, eabk1692 (2022).
- 1166 74. Honkala, A.T., Taylor, D. & Malhotra, S.V. Guanylate-Binding Protein 1: An Emerging Target in
1167 Inflammation and Cancer. *Front Immunol* **10**, 3139 (2019).
- 1168 75. Hu, Z.W. *et al.* Ferroptosis Driver SOCS1 and Suppressor FTH1 Independently Correlate With
1169 M1 and M2 Macrophage Infiltration in Head and Neck Squamous Cell Carcinoma. *Front Cell*
1170 *Dev Biol* **9**, 727762 (2021).
- 1171 76. Moll, H., Flohe, S. & Rollinghoff, M. Dendritic cells in Leishmania major-immune mice harbor
1172 persistent parasites and mediate an antigen-specific T cell immune response. *Eur J Immunol*
1173 **25**, 693-699 (1995).
- 1174 77. Lee, S.H. *et al.* Mannose receptor high, M2 dermal macrophages mediate nonhealing
1175 Leishmania major infection in a Th1 immune environment. *J Exp Med* **215**, 357-375 (2018).
- 1176 78. Romano, A. *et al.* Divergent roles for Ly6C+CCR2+CX3CR1+ inflammatory monocytes during
1177 primary or secondary infection of the skin with the intra-phagosomal pathogen Leishmania
1178 major. *PLoS Pathog* **13**, e1006479 (2017).
- 1179 79. Tietscher, S. *et al.* A comprehensive single-cell map of T cell exhaustion-associated immune
1180 environments in human breast cancer. *Nat Commun* **14**, 98 (2023).
- 1181 80. Adema, G.J. *et al.* A dendritic-cell-derived C-C chemokine that preferentially attracts naive T
1182 cells. *Nature* **387**, 713-717 (1997).
- 1183 81. Cardoso, A.P. *et al.* The immunosuppressive and pro-tumor functions of CCL18 at the tumor
1184 microenvironment. *Cytokine Growth Factor Rev* **60**, 107-119 (2021).
- 1185 82. Rao, L.Z. *et al.* IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis
1186 by repressing IL-4-induced M2 program in macrophages. *Cell Death Differ* **28**, 1270-1283
1187 (2021).
- 1188 83. Hsieh, S.L. & Lin, W.W. Decoy receptor 3: an endogenous immunomodulator in cancer
1189 growth and inflammatory reactions. *J Biomed Sci* **24**, 39 (2017).
- 1190 84. del Rio, M.L. *et al.* Immunotherapeutic targeting of LIGHT/LTbetaR/HVEM pathway fully
1191 recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells. *MAbs* **8**, 478-490
1192 (2016).
- 1193 85. Yu, K.Y. *et al.* A newly identified member of tumor necrosis factor receptor superfamily (TR6)
1194 suppresses LIGHT-mediated apoptosis. *J Biol Chem* **274**, 13733-13736 (1999).
- 1195 86. Chang, Y.C. *et al.* Epigenetic control of MHC class II expression in tumor-associated
1196 macrophages by decoy receptor 3. *Blood* **111**, 5054-5063 (2008).
- 1197 87. Aass, K.R., Kastnes, M.H. & Standal, T. Molecular interactions and functions of IL-32. *J Leukoc*
1198 *Biol* **109**, 143-159 (2021).
- 1199 88. Ribeiro-Dias, F. & Oliveira, I.B.N. A Critical Overview of Interleukin 32 in Leishmaniases. *Front*
1200 *Immunol* **13**, 849340 (2022).
- 1201 89. Choi, J.D. *et al.* Identification of the most active interleukin-32 isoform. *Immunology* **126**,
1202 535-542 (2009).
- 1203 90. Wallimann, A. & Schenk, M. IL-32 as a potential biomarker and therapeutic target in skin
1204 inflammation. *Front Immunol* **14**, 1264236 (2023).

- 1205 91. Moulik, S. *et al.* Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal
1206 Leishmaniasis. *Clin Infect Dis* **66**, 404-410 (2018).
- 1207 92. Sundar, S. & Rai, M. Laboratory diagnosis of visceral leishmaniasis. *Clin Diagn Lab Immunol* **9**,
1208 951-958 (2002).
- 1209 93. de Bruijn, M.H. & Barker, D.C. Diagnosis of New World leishmaniasis: specific detection of
1210 species of the *Leishmania braziliensis* complex by amplification of kinetoplast DNA. *Acta*
1211 *Trop* **52**, 45-58 (1992).
- 1212 94. Celeste, B.J., Angel, S.O., Castro, L.G., Gidlund, M. & Goto, H. *Leishmania infantum* heat
1213 shock protein 83 for the serodiagnosis of tegumentary leishmaniasis. *Braz J Med Biol Res* **37**,
1214 1591-1593 (2004).
- 1215 95. de Oliveira, A.P. *et al.* Comparison of flow cytometry and indirect immunofluorescence assay
1216 in the diagnosis and cure criterion after therapy of American tegumentary leishmaniasis by
1217 anti-live *Leishmania (Viannia) braziliensis* immunoglobulin G. *J Immunol Methods* **387**, 245-
1218 253 (2013).
- 1219 96. Mao, S., Zhang, Y., Seelig, G. & Kannan, S. CellMeSH: probabilistic cell-type identification
1220 using indexed literature. *Bioinformatics* **38**, 1393-1402 (2022).
- 1221 97. Dos Santos, J.C. *et al.* Cytokines and microbicidal molecules regulated by IL-32 in THP-1-
1222 derived human macrophages infected with New World *Leishmania* species. *PLoS Negl Trop*
1223 *Dis* **11**, e0005413 (2017).
- 1224
- 1225